simvastatin has been researched along with Atherogenesis in 203 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 72 (35.47) | 29.6817 |
| 2010's | 116 (57.14) | 24.3611 |
| 2020's | 15 (7.39) | 2.80 |
| Authors | Studies |
|---|---|
| Katselou, MG; Kourounakis, AP; Matralis, AN; Nikitakis, A | 1 |
| Kourounakis, AP; Ladopoulou, E; Matralis, AN | 1 |
| Kourounakis, AP; Matralis, AN | 1 |
| Bacchin, ASF; Bianco, HT; Caixeta, A; Damasceno, NRT; Fonseca, FA; França, CN; Izar, MCO; Mello, APQ; Moreira, FT; Neto, AMF; Pinto, LCS; Póvoa, RMS | 1 |
| Alves Barros, AS; Barbosa, R; Cesar Matias Pereira, A; de Oliveira Carvalho, H; Faria E Souza, BS; Fernandes, CP; Leticia Elizandra Boettger, M; Lobato Duarte, J; Maciel Ferreira, A; Maciel Ferreira, I; Santos Rodrigues, AP; Tavares Carvalho, JC | 1 |
| Bae, E; Han, SW; Kim, JE; Kim, YS; Lee, S; Moon, JJ; Park, DJ; Yang, SH; Yu, MY | 1 |
| He, H; He, J; Liu, J; Liu, X; Ma, S; Xu, F; Zhang, M; Zhang, W; Zhou, X | 1 |
| Lu, C; Ning, X; Wang, H; Wang, L; Wang, M; Wang, Y; Xing, G; Yu, A; Zhao, R | 1 |
| Hu, YX; Jing, Q; Li, FF; Liang, C; Liang, YL; Qin, YW; You, HM; Zhao, XX; Zhu, RF | 1 |
| Hong, S; Hou, C; Jiang, X; Lin, Q; Sheng, W; Wang, T; Ye, X; Zhang, Y; Zhao, J | 1 |
| Baxter, S; Binderup, T; Calcagno, C; Carlucci, G; Duivenvoorden, R; Fay, F; Fayad, ZA; Fisher, EA; Frederico, YCA; Granada, JF; Hutten, BA; Ishino, S; Karakatsanis, N; Kjaer, A; Lobatto, ME; Lyashchenko, S; Malkus, J; Mani, V; Mulder, WJM; Nahrendorf, M; Pérez-Medina, C; Ramachandran, S; Reiner, T; Robson, PM; Sanchez-Gaytan, B; Senders, ML; Soultanidis, G; Swirski, FK; Tang, J; Teunissen, AJP; van Leent, MMT; Zhao, Y | 1 |
| Altamirano, A; Chen, X; Dai, Y; Li, Y; Sun, Y; Wang, L; Wei, G; Yan, Z; Zhang, T; Zhao, T; Zhao, X; Zhu, J | 1 |
| Agrawal, A; Ahmad, M; Ahmad, T; Ghosh, B; Khanna, K; Kulshreshtha, A; Singh, S | 1 |
| Li, SJ; Li, YP; Ma, LN; Shen, ML; Wu, XD; Yao, SY; Zhang, MM | 1 |
| He, J; Liu, J; Yang, Y; Zhang, W; Zhou, X | 1 |
| Huang, L; Huang, Y; Nie, W; Wei, W; Wu, G; Xi, X; Xie, HY; Yuan, L; Zhang, J; Zuo, L | 1 |
| Abuduwaili, N; Guli, A; Jiang, L; Liu, X; Maney, K; Nabi, X; Sailike, J; Sun, X; Tuoliuhan, H; Wang, Y; Wu, Y | 1 |
| Cui, K; Jiang, Q; Sheng, L; Sun, H | 1 |
| Li, J; Li, Y; Liu, Y; Mu, D; Qi, Y; Shen, S; Sun, X; Xu, B; Zhang, B | 1 |
| Cao, Y; Darwitan, A; Das, P; Muktabar, A; Ng, KW; Nguyen, LTH; Rakshit, M; Tang, J; Venkatraman, S; Vizetto-Duarte, C; Wong, YS | 1 |
| Iswahyudi, M; Prasasty, VD; Setyowati, S; Sinaga, E | 1 |
| Barros, AS; Carvalho, HO; Carvalho, JCT; da Cunha, EL; E Souza, BSF; Ferreira, IM; Taglialegna, T | 1 |
| Guo, J; Liu, Q; Lu, M; Luo, D; Rong, X; Tang, F; Wang, H; Yang, Y; Yin, M; Yu, L | 1 |
| Chen, TP; Gao, DS; Hu, SG; Kang, PF; Li, H; Li, MN; Wang, HJ; Zhang, H; Zhu, J | 1 |
| Bemtgen, X; Bode, C; Grundmann, S; Helbing, T; Hoefer, I; Hohnloser, C; Jaenich, C; Juschkat, M; Kreuzaler, S; Martin, J; Mastroianni, J; Moser, M; Pankratz, F; Pasterkamp, G; Schneider, L; Smolka, C; Zeiser, R | 1 |
| Al Awadhi, M; Al Mahmeed, W; Al Tamimi, O; Al-Hinai, AT; Al-Mahruqi, F; Al-Rasadi, K; Al-Zakwani, I; Arafah, M; Santos, RD; Shehab, A | 1 |
| Ballantyne, CM; Baum, SJ; Davidson, MH; Koren, A; Langslet, G; Mandel, J; McCullough, PA; Sanganalmath, SK; Shah, PK | 1 |
| Dhanerawala, Z; Fajardo Ramirez, OR; García-Cardeña, G; Slegtenhorst, BR; Tullius, SG; Zhang, Y | 1 |
| Chen, X; Li, Y; Lin, L; Wang, S; Zhang, H | 1 |
| Chong, GH; Ghazali, HM; Hamzah, H; Tan, CX | 1 |
| He, J; Liu, J; Zhang, M; Zhang, W | 1 |
| Liu, G; Liu, M; Wang, M | 1 |
| Advani, S; Brunette, CA; Hau, C; MacMullen, L; Majahalme, N; Miller, SJ; Vassy, JL; Zimolzak, AJ | 1 |
| Chrøis, KM; Dela, F; Dohlmann, TL; Hansen, M; Helge, JW; Kelly, B; Kuhlman, ACB; Larsen, S; Morville, T; Sahl, RE | 1 |
| Cheung, LK; Chow, DS; El-Zailik, A; Sherman, V; Wang, Y | 1 |
| Aquino, M; Baber, U; Barman, N; Camaj, A; Chandrasekhar, J; Claessen, B; Dangas, G; Faggioni, M; Farhan, S; Guedeney, P; Kalkman, DN; Kini, A; Kovacic, JC; Mehran, R; Moreno, P; Shah, S; Sharma, S; Sorrentino, S; Sweeny, J; Vijay, P; Vogel, B | 1 |
| Akimoto, H; Inoue, N; Kobayashi, D; Negishi, A; Numajiri, S; Ohshima, S; Okita, M; Oshima, S | 1 |
| Chan, P; Liu, Z; Ma, YB; Tomlinson, B; Zhang, Y | 1 |
| Li, M; Qi, Z; Zhang, J; Zhu, K | 1 |
| Fan, S; Ge, J; Hu, K; Jia, L; Jin, X; Liu, X; Ma, X; Sun, A; Wang, C; Wang, K; Wang, S; Zhao, B; Zhao, H; Zhao, J; Zhao, T; Zhu, H; Zou, Y | 1 |
| Barter, PJ; Karlson, BW; Lundman, P; Nicholls, SJ; Palmer, MK | 3 |
| Chen, RZ; Ge, JB; Jia, JG; Jiang, H; Liu, M; Yu, P; Yu, Y; Zhang, L; Zhang, PP; Zou, YZ | 1 |
| Li, F; Shen, Y; Wang, CH; Wang, YQ; Zhang, W | 1 |
| Havekes, LM; Heemskerk, MM; Jukema, JW; Kühnast, S; Louwe, MC; Pieterman, EJ; Princen, HM; Rensen, PC; Smit, JW; van den Berg, SA; van der Hoorn, JW; van Klinken, JB | 1 |
| Anderson, DC; Boden, WE; Chaitman, BR; Cruz-Flores, S; Goldstein, LB; Grant, S; Kostuk, WJ; Padley, RJ; Sila, CA; Teo, KK; Weintraub, WS | 1 |
| Baumgarten, G; Frede, S; Hilbert, T; Hoeft, A; Klaschik, S; Knuefermann, P; Poth, J | 1 |
| Aras, R; Atta, AM; Atta, ML; Couto, RD; Pereira, MM; Santos, TP | 1 |
| Adekunle, AS; Adelusi, TI; Fatoki, JO | 1 |
| Feng, L; Guo, ZG; Li, MX; Qin, YF; Sun, YX; Tian, D; Ying, R; Yuan, Y | 1 |
| Barathi, VA; Guymer, RH; Luu, CD; Wong, TY; Yeo, SW | 1 |
| Ballantyne, CM; Cain, VA; Hoogeveen, RC; Karlson, BW; Palmer, MK; Raya, JL | 1 |
| Attias, J; Aviram, M; Hamoud, S; Hayek, T; Moscoviz, D; Rosenblat, M; Volkova, N | 1 |
| Bauer, I; Bertolotto, M; Dallegri, F; Fabre, M; Galan, K; Lenglet, S; Mach, F; Montecucco, F; Nencioni, A; Palombo, D; Pane, B; Pelli, G; Pende, A; Python, M; Quercioli, A; Spinella, G; Vuilleumier, N | 1 |
| Anticoli, S; Gambardella, L; Malorni, W; Maselli, A; Matarrese, P; Panusa, A; Ruggieri, A; Vona, R | 1 |
| Ashok, P; Poulose, DN; Singh, D; Suresh, B | 1 |
| Cavasin, MA; Chonchol, M; Demos-Davies, KM; Jablonski, K; Keenan, AL; Kendrick, J; Levi, M; Masuda, M; Masuda, R; McKinsey, TA; Miyazaki, M; Miyazaki-Anzai, S; Saunders, SJ | 1 |
| Jin, YH; Li, TH; Liu, M; Shi, LH; Zhu, BQ | 1 |
| Frazee, SG; Garavaglia, SB; Jackevicius, CA; Krumholz, HM; Levin, R; Novshadian, H; Ross, JS; Stettin, G | 1 |
| Li, Q; Lu, F; Wang, H; Wang, Q; Yan, S; Zhu, W; Zhu, X | 1 |
| Schetz, D; Sein Anand, J | 1 |
| Bao, XC; Gao, XQ; Ji, XP; Li, HW; Qiu, YH; Wu, Z; Xue, L; Yang, XF; Zhu, XH | 1 |
| Augusti, PR; Conte, L; da Veiga, ML; Denardin, IT; Duarte, MM; Emanuelli, T; Figueiredo, CG; Kasten, J; Quatrin, A; Roehrs, M; Ruviaro, AR; Somacal, S | 1 |
| Chen, L; Chen, P; Hu, LQ; Li, HQ; Li, TT; Rong, R; Tang, J; Yin, CS; Zhang, Q | 1 |
| Jiao, P; Qin, S; Song, G; Sun, X; Tian, H; Tian, S; Wu, Y; Yao, S; Yu, Y; Zhai, L; Zhang, X; Zhang, Z; Zhao, H; Zong, C | 1 |
| Gdula-Dymek, A; Krysiak, R; Marek, B; Okopień, B | 2 |
| Hu, Y; Liu, K; Miao, C; Ren, L; Sun, B; Yan, M; Zhang, Y | 1 |
| Chartrand, MS; Hazilawati, H; Hemn, HO; Noordin, MM; Rahman, HS; Zuki, A | 1 |
| Amarenco, P; Bangalore, S; DeMicco, DA; Fayyad, R; Kastelein, JJ; Laskey, R; Waters, DD | 1 |
| Alexopoulos, D; Apostolakis, E; Hahalis, G; Koniari, I; Mavrilas, D; Papadaki, H; Papadimitriou, E; Papalois, A; Poimenidi, E; Xanthopoulou, I | 1 |
| Banach, M; Bittner, V; Hovingh, GK; Kastelein, JJ; Lip, GY; Mikhailidis, DP; Ray, K; Rysz, J; Sahebkar, A; Serban, C; Undas, A; Ursoniu, S; Watts, GF | 1 |
| Butler, CR; O'Hare, AM | 1 |
| Li, M; Peng, L; Xu, Y; Yang, C; Zhang, G; Zhang, J; Zhou, Y | 1 |
| Babaei, A; Bahrami, G; Bahrami, MT; Farzaei, MH; Miraghaee, S; Mohammadi, B; Saidi, MR | 1 |
| Jiao, R; Li, L; Qian, Y; Zhang, HZ; Zhang, Y | 1 |
| Alaarg, A; da Silva, AE; Hamers, AA; Metselaar, JM; Schulte, DM; Storm, G; Stroes, ES; van der Valk, FM; van Ufford, LC; Versloot, M; Zheng, KH | 1 |
| Alomrani, AH; Badran, MM; Harisa, GI | 1 |
| Lu, M; Tang, F; Wang, H; Yang, X; Yin, M; Yu, L; Zhang, Y | 1 |
| Chai, YS; Fu, WJ; Ke, J; Lei, T; Nie, H; Pan, JH; Paranjpe, M; Qu, L; Wang, ZH; Wu, G; Xu, RH; Xu, XY; Yan, YX; Yin, Z | 1 |
| Li, Y; Liu, J; Pang, X; Si, J; Xu, S | 1 |
| Barthwal, MK; Dikshit, M; Farooqui, M; Jain, M; Kanshana, JS; Khanna, V; Kumar, S; Misra, A; Singh, V | 1 |
| Almeida, MR; Almeida, TI; Barauna, VG; Davel, AP; Fernandes, GJ; Garcia, JA; Magalhães, SF; Santos, L; Soares, EA | 1 |
| Abuelezz, SA; Atalla, SS; El Aziz, LFA; Gorge, SS; Mohamed, MT | 1 |
| Chen, K; Guo, Y; Pan, L; Wen, J; Xu, H; Zhou, M | 1 |
| Blumenthal, RS; Musunuru, K | 1 |
| Davidson, M; Robinson, JG | 1 |
| Chen, K; Liao, W; Pan, L; Wen, J; Xu, H; Zhou, M | 1 |
| Agrotis, A | 1 |
| Chade, AR; Grande, JP; Krier, JD; Lerman, A; Lerman, LO; Zhu, XY | 1 |
| Lepor, NE; McCullough, PA | 1 |
| Baker, AB; Beigel, R; Chatzizisis, YS; Coskun, AU; Daley, W; Edelman, ER; Feldman, CL; Gerrity, RG; Jonas, M; Maynard, C; Stone, BV; Stone, PH | 1 |
| Hamilton-Craig, IR | 1 |
| Kozlov, VA; Shirinskiĭ, IV; Shirinskiĭ, VS; Zheltova, OI | 1 |
| Spence, JD | 1 |
| Pazianas, M | 1 |
| Bedani, R; Bomdespacho, LQ; Cavallini, DC; Rossi, EA; Vendramini, RC | 1 |
| Aragoncillo, P; Fernández-Cruz, A; Gómez-Garre, D; González-Rubio, ML; Granados, R; Muñoz-Pacheco, P | 1 |
| Gryglewski, R; Hassan, M; Heeba, G; Khalifa, M; Malinski, T; Moselhy, ME | 1 |
| Chang-qing, S; Kai-min, L; Qiang, X; Rong, W; Wei-hua, L | 1 |
| Alcudia, JF; Badimon, L; Guadall, A; Martínez-González, J; Raposo, B; Rodríguez, C; Sánchez-Gómez, S | 1 |
| Chu, L; Jiang, Y; Li, J; Si, Q; Wang, J; Wu, Y; Zhang, J | 1 |
| Beronov, K; Cicha, I; Daniel, WG; Garlichs, CD; Goppelt-Struebe, M; Osterode, K; Raaz, D; Ramirez, EL; Yilmaz, A | 1 |
| Bowsman, M; Chen, M; Cordover, D; Fordstrom, P; Hale, C; Helmering, J; Kaufman, SA; Lloyd, DJ; Véniant, MM; Wang, M; Zhou, M | 1 |
| Cioffi, G; Cramariuc, D; Devereux, RB; Gerdts, E; Ray, S; Rieck, AE; Staal, EM; Wachtell, K | 1 |
| Dumesnil, JG; Pibarot, P | 1 |
| Bobková, D; Havlíčková, J; Kovář, J; Pitha, J; Poledne, R | 1 |
| Cai, C; Cai, Q; Du, X; Kermany, MH; Yoo, T; Zhang, C; Zhou, B | 1 |
| Antonopoulou, S; Demopoulos, CA; Iatrou, C; Iliopoulos, DG; Karantonis, HC; Perrea, DN; Theocharis, SE; Tsantila, N | 1 |
| Tomkin, GH | 1 |
| Fan, W; Fu, X; Gu, X; Jia, X; Wei, M; Xue, L; Zhang, J | 1 |
| Feng, JB; Ji, XP; Jiang, H; Liu, CX; Liu, Y; Lu, XT; Wang, R; Wu, YL; Xu, XS; Zhang, C; Zhang, L; Zhang, Y; Zhao, YX | 1 |
| Kaminsky, Y; Kosenko, E; Suslikov, A | 1 |
| Kappagoda, CT; Karalliedde, LD | 1 |
| Ryan, D; Xu, H; Xu, HE | 1 |
| Becker, L; Gharib, SA; Heinecke, JW; Irwin, AD; Oram, JF; Vaisar, T; Wijsman, E | 1 |
| Kim, SH; Lee, BS; Lee, ES; Lee, JY; Moon, DW; Park, JE | 1 |
| Chen, HW; Li, L; Li, N; Liu, RM; Wang, L; Xia, YF; Yao, YM; Yin, YX; Zhai, HX; Zhang, JJ | 1 |
| Arruda, AP; Breder, I; Coope, A; de Oliveira, HC; Dorighello, Gde G; Milanski, M; Razolli, D; Velloso, LA | 1 |
| Boman, K; Brudi, P; Egstrup, K; Gohlke-Baerwolf, C; Holme, I; Kesäniemi, YA; Malbecq, W; Pedersen, TR; Rossebø, AB; Wachtell, K; Willenheimer, R | 1 |
| Pérez, A | 1 |
| Montgomery, BD | 1 |
| Emmott, A; Leask, RL; Rossi, J; Rouleau, L; Tardif, JC | 1 |
| Cai, Z; Chen, L; Cheng, WL; Guo, J; Huang, CX; Ke, YN; Li, H; Wang, P; Wang, Y; Xi, Y | 1 |
| Krumholz, HM | 1 |
| Fan, WH; Jin, B; Li, Y; Luo, XP; Shen, W; Shi, HM | 1 |
| Berkowitz, DE; Bhunia, A; Chang, F; Romer, LH; Ryoo, S; Shoukas, A | 1 |
| Insull, W; Jiang, P; Krause, S; Padley, RJ; Parreno, RA; Superko, HR; Thakkar, RB; Toth, PP | 1 |
| Brown, BG; Cheung, MC; Dobiásová, M; Frohlich, J; Sedová, M | 1 |
| Li, G; Liu, J; Qin, S; Song, G; Tian, H; Yao, S; Yu, Y; Zhao, Z | 1 |
| Chen, Y; Chen, Z; Flattery, AM; Geoghagen, N; Hubbard, BK; Lassman, ME; McLaughlin, T; Pan, Y; Roddy, TP; Stefanni, AC; Strack, AM; Urosevic-Price, O; Wang, L; Wong, KK; Wu, W | 1 |
| Davis, HR; Lowe, RS; Neff, DR | 1 |
| Kaminsky, Y; Kosenko, E; Suslikov, A; Tikhonova, L | 1 |
| Kalhan, A; Rees, A | 1 |
| Badimon, L; Cal, R; Camino-López, S; Casani, L; Juan-Babot, O; Llenas, A; Llorente-Cortes, V; Sendra, J | 1 |
| Anderson, JD; Berr, SS; Chew, JD; Christopher, JM; DiMaria, JM; Epstein, FH; Hagspiel, KD; Harthun, NL; Hunter, JR; Kramer, CM; Meyer, CH; Wang, H; West, AM; Winberry, GB | 1 |
| Alique, M; Badimon, JJ; Cimmino, G; Connolly, TM; Feuerstein, G; Fuster, V; Giannarelli, C; Ibanez, B; Ruiz, JM; Zafar, MU | 1 |
| Catapano, AL; Norata, GD; Pirillo, A | 1 |
| Turagam, M; Velagapudi, P | 1 |
| Oroma Owira, PM; Xulu, S | 1 |
| Bian, Y; Dou, L; Li, J; Lu, Y; Man, Y; Qin, W; Shen, T; Wang, S; Xiao, C; Zhan, C | 1 |
| Kong, W; Zhu, Y | 1 |
| Anderson, T; Boden, WE; Chaitman, BR; Desvignes-Nickens, P; Koprowicz, K; McBride, R; Probstfield, JL; Teo, K; Weintraub, W | 1 |
| Hoffmann, MM; Jacob, S; Konrad, T; Müller-Schewe, T; Winkler, K | 1 |
| Chapman, MJ | 1 |
| Chen, KJ; Guo, CY; Huang, Y; Ma, XJ; Shi, DZ; Wu, CF; Xue, M; Yin, HJ | 1 |
| Bai, W; Li, H; Zheng, X; Zhou, L | 1 |
| Green, D; McDonald, J; O'Riordan, E; Panayotova, R; Ritchie, JP | 1 |
| Bożentowicz-Wikarek, M; Chudek, J; Kocełak, P; Olszanecka-Glinianowicz, M; Smertka, M | 1 |
| Li, LJ; Li, M; Peng, L; Xu, YZ; Yang, C; Zhang, GY; Zhang, JP; Zhou, YN | 1 |
| Hu, JP; Liu, P; Mao, MJ; Wang, C; Zhang, YY | 1 |
| Hot, A; Lavocat, F; Lenief, V; Miossec, P | 1 |
| Gdula-Dymek, A; Krysiak, R; Okopien, B | 1 |
| Fang, Y; Li, F; Qin, S; Sang, H; Wang, J; Yao, S; Yuan, N | 1 |
| Armitage, J; Chen, F; Chen, YP; Chen, ZM; Feng, F; Gao, Y; Hopewell, JC; Hundei, WB; Jiang, LX; Landray, M; Li, J; Li, X; Liu, JM; Valdes-Marquez, E; Zhang, D; Zhang, HB | 1 |
| Borthwick, F; Cheeseman, CI; Hassanali, Z; Mangat, R; Proctor, SD; Russell, JC; Uwiera, RR; Vine, DF; Warnakula, S | 1 |
| Rosenson, RS | 1 |
| Anderson, D; Bula, RL; Gulaya, V; Lankford, B; Lapu-Bula, R; Oduwole, A; Ofili, E; Pemu, PI | 1 |
| Field, KM | 1 |
| Chandalia, M; Jialal, I | 1 |
| Briestensky, J; Jamborova, G; Jaynes, R; Kopecky, M; Nachtigal, P; Pospechova, K; Pospisilova, N; Santar, I; Semecky, V; Smahelova, A; Solichova, D; Zdansky, P | 1 |
| Allen, C; Amabile, N; Barrios, V; Chen, JW; Johnson-Levonas, AO; Massaad, R; Paganelli, F; Vandormael, K | 1 |
| Bots, AF; Kastelein, JJ | 1 |
| Borges, JL | 1 |
| Butticè, G; Miller, J; Smith, BD; Wang, L | 1 |
| Barillà, A; Belghity, N; Buemi, M; Caccamo, C; Crascì, E; Floccari, F; Frisina, N; Mantuano, S; Nostro, L; Pacilè, ME; Pernice, F; Romeo, A | 1 |
| Aarsetøy, H; Brügger-Andersen, T; Grundt, H; Hetland, Ø; Nilsen, DW | 1 |
| Fukuo, K; Katuya, T; Kawamoto, H; Kotani, N; Ogihara, T; Sugimoto, K; Suzuki, A; Takemura, Y; Yasuda, O; Yokoi, T | 1 |
| Busser, E; de Kleijn, DP; de Vries, JP; Koekkoek, JA; Moll, FL; Pasterkamp, G; Schoneveld, A; van der Wal, AC; Velema, E; Verheijen, JH; Verhoeven, BA; Virmani, R | 1 |
| Anderson, JL; Horne, BD; Jensen, JR; Lanman, RB; Lavasani, F; May, HT; Muhlestein, JB; Pearson, RR; Wolfert, RL; Yannicelli, HD | 1 |
| Dubey, L; Pu, J; Wang, L; Yang, X; Zeng, H; Zhou, N | 1 |
| Hou, M; Ling, W; Ma, J; Tang, Z; Wang, Q; Xia, M; Xia, X; Zhu, H | 1 |
| Aprahamian, T; Bonegio, R; Lefer, DJ; Perlman, H; Rifkin, IR; Rizzo, J; Walsh, K | 1 |
| Baba, K; Hayabuchi, N; Imaizumi, T; Ishibashi, M; Kai, H; Kaida, H; Nakaura, H; Tahara, N | 1 |
| Chu, B; Hatsukami, TS; Phan, BA; Polissar, N; Yuan, C; Zhao, XQ | 1 |
| Kotyla, PJ; Kucharz, EJ; Sliwinska-Kotyla, B | 1 |
| Aukrust, P; Boullier, A; Breland, U; Damås, JK; Fevang, B; Frøland, SS; Gullestad, L; Halvorsen, B; Hansson, GK; Kjekshus, J; Ovchinnikova, O; Quehenberger, O; Robertson, AK; Sandberg, WJ; Smith, C; Taskén, K; Waehre, T; Yndestad, A; Øie, E | 1 |
| Chang, LT; Chua, S; Fu, M; Sun, CK; Wu, CJ; Yip, HK | 1 |
| Chen, X; Li, Z; Meng, L; Qin, XW; Ruan, YM; Yang, YJ; Zhang, HD | 1 |
| Cicha, I; Daniel, WG; Garlichs, CD; Goppelt-Struebe, M; Muehlich, S; Raaz, D; Yilmaz, A | 1 |
| Balcerak, M; Broncel, M; Chojnowska-Jezierska, J | 1 |
| Fayad, ZA; Machac, J; Rudd, JH | 1 |
| Vaverková, H | 1 |
| Angri, V; Calabrò, P; Chiariello, M; Cirillo, P; De Rosa, S; Fiorentino, I; Gargiulo, A; Musto D'Amore, S; Pacileo, M; Petrillo, G; Prevete, N; Sasso, L; Ucci, G | 1 |
| Dollerup, J; Gormsen, LC; Mogensen, CE; Nellemann, B; Nielsen, S; Rasmussen, LM; Schmitz, O | 1 |
| Chen, JW; Chen, YH; Huang, SL; Leu, HB; Lin, CP; Liu, PL; Liu, TZ | 1 |
| Li, F; Wang, CH; Zhang, W; Zhu, WZ | 1 |
| Chung, HY; Kim, HJ; Lee, JS; Noh, JS; Song, SH; Song, YO; Suh, H | 1 |
| Hu, WL; Li, JJ; Qian, SB; Qiao, SB | 1 |
| Abe, K; Deguchi, K; Hayashi, T; Kamiya, T; Lukic, V; Nagotani, S; Sehara, Y; Tsuchiya, A; Yamashita, T; Zhang, H | 1 |
| Padial, LR | 1 |
| Chumark, P; Khunawat, P; Morales, NP; Phivthong-Ngam, L; Phornchirasilp, S; Pongrapeeporn, KU; Ratanachamnong, P; Sanvarinda, Y; Srisawat, S | 1 |
| Drüeke, TB; Ivanovski, O; Joki, N; Ketteler, M; Lacour, B; Maizel, J; Massy, ZA; Mothu, N; Nguyen-Khoa, T; Nikolov, IG; Szumilak, D; Westenfeld, R | 1 |
| Greenland, P; Lloyd-Jones, D | 1 |
| Aparicio, C; Blanco-Colio, LM; Egido, J; Esbrit, P; Martin-Ventura, JL; Ortega, L | 1 |
| Liu, Y; Yan, F; Yu, H; Zhang, C; Zhang, Y; Zhao, Y | 1 |
| Bastos, MG; Suassuna, PG | 1 |
| Stein, EA | 1 |
| Chen, SJ; Chiu, JJ; Hou, CJ; Shiao, MS; Su, CH; Tsai, CH; Wu, YJ; Yeh, HI | 1 |
| Devaraj, S; Jialal, I; Rockwood, J; Wang, L; Zak, D | 1 |
14 review(s) available for simvastatin and Atherogenesis
| Article | Year |
|---|---|
Evaluating the efficacy and safety of atorvastatin + ezetimibe in a fixed-dose combination for the treatment of hypercholesterolemia.
Topics: Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Cardiovascular Diseases; Drug Combinations; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Risk Factors; Simvastatin | 2019 |
Achievement of 2011 European low-density lipoprotein cholesterol (LDL-C) goals of either <70 mg/dl or ≥ 50% reduction in high-risk patients: results from VOYAGER.
Topics: Aged; Atherosclerosis; Atorvastatin; Cholesterol, LDL; Europe; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrimidines; Pyrroles; Risk Factors; Risk Reduction Behavior; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2013 |
To what extent do high-intensity statins reduce low-density lipoprotein cholesterol in each of the four statin benefit groups identified by the 2013 American College of Cardiology/American Heart Association guidelines? A VOYAGER meta-analysis.
Topics: Adolescent; Adult; Aged; Atherosclerosis; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Databases, Factual; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Least-Squares Analysis; Male; Middle Aged; Odds Ratio; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Risk; Rosuvastatin Calcium; Simvastatin; Young Adult | 2015 |
Doses of rosuvastatin, atorvastatin and simvastatin that induce equal reductions in LDL-C and non-HDL-C: Results from the VOYAGER meta-analysis.
Topics: Atherosclerosis; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Rosuvastatin Calcium; Simvastatin | 2016 |
The impact of statin therapy on plasma levels of von Willebrand factor antigen. Systematic review and meta-analysis of randomised placebo-controlled trials.
Topics: Adult; Aged; Antigens; Atherosclerosis; Atorvastatin; Cardiovascular Diseases; Fatty Acids, Monounsaturated; Female; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Male; Middle Aged; Pravastatin; Randomized Controlled Trials as Topic; Regression Analysis; Risk Assessment; Rosuvastatin Calcium; Simvastatin; Thrombosis; von Willebrand Factor; Young Adult | 2016 |
Lipids, biomarkers, and noninvasive imaging of atherosclerotic disease activity in clinical trials.
Topics: Atherosclerosis; Biomarkers; Cardiovascular Physiological Phenomena; Cholesterol, LDL; Clinical Trials as Topic; Humans; Magnetic Resonance Angiography; Positron-Emission Tomography; Simvastatin; Treatment Outcome | 2008 |
Effects of ezetimibe on atherosclerosis in preclinical models.
Topics: Animals; Anticholesteremic Agents; Apolipoproteins B; Apolipoproteins E; Atherosclerosis; Azetidines; Cardiovascular Diseases; Cholesterol, LDL; Disease Models, Animal; Drug Evaluation, Preclinical; Ezetimibe; Mice; Mice, Knockout; Rabbits; Risk; Simvastatin | 2011 |
Pitavastatin: novel effects on lipid parameters.
Topics: Apolipoprotein A-I; Apolipoproteins B; Atherosclerosis; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials, Phase III as Topic; Clinical Trials, Phase IV as Topic; Coronary Artery Disease; Double-Blind Method; Dyslipidemias; Europe; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Japan; Lipids; Multicenter Studies as Topic; Plaque, Atherosclerotic; Pyrroles; Quinolines; Randomized Controlled Trials as Topic; Russia; Simvastatin; Triglycerides | 2011 |
Lipid-lowering therapy in chronic kidney disease: is there a role for ezetimibe?
Topics: Anticholesteremic Agents; Atherosclerosis; Azetidines; Drug Therapy, Combination; Ezetimibe; Humans; Renal Dialysis; Renal Insufficiency, Chronic; Simvastatin | 2012 |
Low high-density lipoprotein cholesterol disorders and cardiovascular risk: contribution of associated low-density lipoprotein subclass abnormalities.
Topics: Atherosclerosis; Cardiovascular Diseases; Cholesterol; Cholesterol, HDL; Gemfibrozil; Humans; Hypolipidemic Agents; Lipoproteins, LDL; Lovastatin; Risk Factors; Simvastatin | 2005 |
Effect of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on high-sensitivity C-reactive protein levels.
Topics: Animals; Atherosclerosis; Atorvastatin; C-Reactive Protein; Cardiovascular Diseases; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Metabolic Syndrome; Pravastatin; Pyrroles; Risk Factors; Simvastatin | 2005 |
[Influence of combined, hypolipemic therapy on lipids and non-lipid atherosclerosis risk factors].
Topics: Anticholesteremic Agents; Atherosclerosis; Azetidines; Cholesterol, HDL; Cholesterol, LDL; Clofibric Acid; Drug Therapy, Combination; Ezetimibe; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipids; Niacin; Risk Factors; Simvastatin | 2007 |
[Dual inhibition of cholesterol using the drug combination ezetimibe/simvastatin?].
Topics: Anticholesteremic Agents; Atherosclerosis; Azetidines; Cholesterol, LDL; Drug Combinations; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Simvastatin | 2007 |
Ezetimibe plus simvastatin cardiovascular outcomes study program.
Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Aortic Valve Stenosis; Atherosclerosis; Azetidines; Disease Progression; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Kidney Failure, Chronic; Simvastatin; Treatment Outcome | 2008 |
31 trial(s) available for simvastatin and Atherogenesis
| Article | Year |
|---|---|
Main differences between two highly effective lipid-lowering therapies in subclasses of lipoproteins in patients with acute myocardial infarction.
Topics: Aged; Atherosclerosis; Cholesterol; Cholesterol, LDL; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Lipoproteins; Liver; Male; Middle Aged; Rosuvastatin Calcium; Simvastatin; ST Elevation Myocardial Infarction | 2021 |
Drug effect of atorvastatin on middle cerebral atherosclerotic stenosis and high resolution NMR diagnosis.
Topics: Aged; Atherosclerosis; Atorvastatin; Constriction, Pathologic; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Magnetic Resonance Imaging; Male; Middle Aged; Middle Cerebral Artery; Pravastatin; Rosuvastatin Calcium; Simvastatin | 2018 |
Comparison and analysis of the therapeutic effect of different statins in the treatment of atherosclerosis.
Topics: Adult; Aged; Atherosclerosis; Atorvastatin; Carotid Arteries; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Middle Aged; Nitric Oxide; Nitric Oxide Synthase; Plaque, Atherosclerotic; Pravastatin; Simvastatin | 2018 |
The Integrating Pharmacogenetics in Clinical Care (I-PICC) Study: Protocol for a point-of-care randomized controlled trial of statin pharmacogenetics in primary care.
Topics: Adult; Aged; Atherosclerosis; Cholesterol, LDL; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver-Specific Organic Anion Transporter 1; Male; Middle Aged; Muscular Diseases; Pharmacogenomic Testing; Point-of-Care Systems; Precision Medicine; Primary Health Care; Primary Prevention; Secondary Prevention; Simvastatin | 2018 |
Inflammatory biomarkers in patients in Simvastatin treatment: No effect of co-enzyme Q10 supplementation.
Topics: Adult; Aged; Atherosclerosis; Biomarkers; C-Reactive Protein; Cytokines; Double-Blind Method; Female; Glycated Hemoglobin; Humans; Inflammation; Male; Middle Aged; Simvastatin; Ubiquinone | 2019 |
Extended-release niacin therapy and risk of ischemic stroke in patients with cardiovascular disease: the Atherothrombosis Intervention in Metabolic Syndrome with low HDL/High Triglycerides: Impact on Global Health Outcome (AIM-HIGH) trial.
Topics: Aged; Atherosclerosis; Brain Ischemia; Delayed-Action Preparations; Female; Follow-Up Studies; Humans; Hypolipidemic Agents; Lipoproteins, HDL; Male; Metabolic Syndrome; Middle Aged; Niacin; Simvastatin; Stroke; Thrombosis; Triglycerides | 2013 |
Efficacy, safety and effect on biomarkers related to cholesterol and lipoprotein metabolism of rosuvastatin 10 or 20 mg plus ezetimibe 10 mg vs. simvastatin 40 or 80 mg plus ezetimibe 10 mg in high-risk patients: Results of the GRAVITY randomized study.
Topics: Absorption; Adult; Atherosclerosis; Azetidines; Biomarkers; Cholesterol, LDL; Coronary Disease; Drug Administration Schedule; Ezetimibe; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Lipoproteins; Male; Pyrimidines; Risk; Rosuvastatin Calcium; Simvastatin; Sitosterols; Sulfonamides; Treatment Outcome | 2014 |
Pomegranate extract (POMx) decreases the atherogenicity of serum and of human monocyte-derived macrophages (HMDM) in simvastatin-treated hypercholesterolemic patients: a double-blinded, placebo-controlled, randomized, prospective pilot study.
Topics: Adult; Animals; Atherosclerosis; Cell Line; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Drug Synergism; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Leukocytes, Mononuclear; Lipids; Lythraceae; Macrophages; Male; Mice; Middle Aged; Monocytes; Oxidative Stress; Oxygen; Pilot Projects; Plant Extracts; Prospective Studies; Reactive Oxygen Species; Simvastatin; Triglycerides | 2014 |
2013 Cholesterol Guidelines Revisited: Percent LDL Cholesterol Reduction or Attained LDL Cholesterol Level or Both for Prognosis?
Topics: Aged; Atherosclerosis; Atorvastatin; Cholesterol, LDL; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Practice Guidelines as Topic; Prognosis; Simvastatin | 2016 |
Low-flow aortic stenosis in asymptomatic patients: valvular-arterial impedance and systolic function from the SEAS Substudy.
Topics: Aged; Aged, 80 and over; Aortic Valve Stenosis; Atherosclerosis; Azetidines; Disease Progression; Double-Blind Method; Drug Combinations; Echocardiography, Doppler; Europe; Ezetimibe, Simvastatin Drug Combination; Female; Hemodynamics; Humans; Hypolipidemic Agents; Logistic Models; Male; Middle Aged; Myocardial Contraction; Predictive Value of Tests; Prospective Studies; Risk Assessment; Risk Factors; ROC Curve; Sensitivity and Specificity; Simvastatin; Systole; Treatment Outcome; United States; Ventricular Dysfunction, Left | 2009 |
Intensive cholesterol-lowering therapy improves large artery elasticity in acute myocardial infarction patients.
Topics: Administration, Oral; Aged; Ankle; Arteries; Atherosclerosis; Biomarkers; Blood Pressure; Brachial Artery; Cholesterol; Cholesterol, LDL; Elasticity; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Linear Models; Male; Middle Aged; Myocardial Infarction; Pulsatile Flow; Simvastatin; Treatment Outcome | 2009 |
Specific and pronounced impacts of lisinopril and lisinopril plus simvastatin on erythrocyte antioxidant enzymes.
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Anticholesteremic Agents; Atherosclerosis; Blood Pressure; Cholesterol, LDL; Drug Synergism; Energy Metabolism; Erythrocytes; Female; Humans; Hypertension; Lisinopril; Male; Middle Aged; Oxidative Stress; Oxidoreductases; Random Allocation; Simvastatin | 2010 |
Observed and predicted reduction of ischemic cardiovascular events in the Simvastatin and Ezetimibe in Aortic Stenosis trial.
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Aortic Valve Stenosis; Apolipoproteins B; Atherosclerosis; Azetidines; Cholesterol, HDL; Cholesterol, LDL; Disease Progression; Dose-Response Relationship, Drug; Drug Therapy, Combination; Echocardiography, Doppler; Ezetimibe; Female; Follow-Up Studies; Humans; Incidence; Male; Middle Aged; Prognosis; Simvastatin; Time Factors | 2010 |
Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease.
Topics: Adult; Aged; Anticholesteremic Agents; Atherosclerosis; Azetidines; Cholesterol, LDL; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Follow-Up Studies; Humans; Incidence; Kidney Failure, Chronic; Male; Middle Aged; Renal Dialysis; Retrospective Studies; Simvastatin; Treatment Outcome | 2010 |
Combination of niacin extended-release and simvastatin results in a less atherogenic lipid profile than atorvastatin monotherapy.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Delayed-Action Preparations; Drug Therapy, Combination; Dyslipidemias; Female; Heptanoic Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins; Magnetic Resonance Spectroscopy; Male; Middle Aged; Niacin; Pyrroles; Simvastatin; Treatment Outcome; United States | 2010 |
Cholesterol esterification and atherogenic index of plasma correlate with lipoprotein size and findings on coronary angiography.
Topics: Antioxidants; Apolipoproteins B; Atherosclerosis; Cholesterol; Coronary Angiography; Coronary Stenosis; Drug Combinations; Esterification; Humans; Lipoproteins; Niacin; Particle Size; Simvastatin | 2011 |
The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol Rationale and study design. The Atherothro
Topics: Anticholesteremic Agents; Atherosclerosis; Azetidines; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Ezetimibe; Humans; Hypolipidemic Agents; Metabolic Syndrome; Niacin; Research Design; Simvastatin; Treatment Outcome | 2011 |
Impacts of lisinopril and lisinopril plus simvastatin on erythrocyte and plasma arginase, nitrite, and nitrate in hypertensive patients.
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Arginase; Atherosclerosis; Drug Therapy, Combination; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Lisinopril; Male; Middle Aged; Nitrates; Nitrites; Simvastatin | 2012 |
The effect of ezetimibe on peripheral arterial atherosclerosis depends upon statin use at baseline.
Topics: Aged; Anticholesteremic Agents; Atherosclerosis; Azetidines; Cholesterol, LDL; Double-Blind Method; Ezetimibe; Female; Femoral Artery; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Magnetic Resonance Imaging; Male; Middle Aged; Peripheral Arterial Disease; Plaque, Atherosclerotic; Prospective Studies; Simvastatin; Treatment Outcome | 2011 |
Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy.
Topics: Aged; Atherosclerosis; Brain Ischemia; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Drug Therapy, Combination; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Kaplan-Meier Estimate; Male; Medication Adherence; Middle Aged; Muscular Diseases; Niacin; Proportional Hazards Models; Simvastatin; Treatment Failure; Triglycerides | 2011 |
Ezetimibe alone and in combination lowers the concentration of small, dense low-density lipoproteins in type 2 diabetes mellitus.
Topics: Aged; Analysis of Variance; Anticholesteremic Agents; Atherosclerosis; Azetidines; Biomarkers; Centrifugation, Density Gradient; Diabetes Mellitus, Type 2; Down-Regulation; Drug Combinations; Ezetimibe; Ezetimibe, Simvastatin Drug Combination; Female; Germany; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Linear Models; Lipoproteins, LDL; Male; Middle Aged; Risk Assessment; Risk Factors; Simvastatin; Time Factors; Treatment Outcome | 2012 |
The effect of fenofibrate on lymphocyte release of proinflammatory cytokines and systemic inflammation in simvastatin-treated patients with atherosclerosis and early glucose metabolism disturbances.
Topics: Adult; Aged; Atherosclerosis; Blood Glucose; C-Reactive Protein; Cytokines; Drug Therapy, Combination; Female; Fenofibrate; Glucose; Glucose Tolerance Test; Humans; Hypolipidemic Agents; Lipids; Lymphocytes; Male; Middle Aged; Simvastatin; Treatment Outcome | 2013 |
Lipid-altering efficacy of switching from atorvastatin 10 mg/day to ezetimibe/simvastatin 10/20 mg/day compared to doubling the dose of atorvastatin in hypercholesterolaemic patients with atherosclerosis or coronary heart disease.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Apolipoproteins B; Atherosclerosis; Atorvastatin; Azetidines; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Drug Therapy, Combination; Europe; Ezetimibe; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Simvastatin; Taiwan; Treatment Outcome | 2005 |
Achieving lipid goals in real life: the Dutch DISCOVERY study.
Topics: Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Netherlands; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome; Triglycerides | 2005 |
Long term influence of regular intake of high dose n-3 fatty acids on CD40-ligand, pregnancy-associated plasma protein A and matrix metalloproteinase-9 following acute myocardial infarction.
Topics: Adult; Age Distribution; Aged; Aged, 80 and over; Atherosclerosis; CD40 Ligand; Corn Oil; Double-Blind Method; Fatty Acids, Omega-3; Female; Humans; Male; Matrix Metalloproteinase 9; Middle Aged; Myocardial Infarction; Pregnancy-Associated Plasma Protein-A; Simvastatin | 2006 |
Fas ligand mRNA levels of circulating leukocytes reflect endothelial dysfunction in hyperlipidemic but not in non-hyperlipidemic patients.
Topics: Aged; Apoptosis; Atherosclerosis; Biomarkers; Brachial Artery; Endothelium, Vascular; Fas Ligand Protein; Female; Humans; Hyperlipidemias; Hypolipidemic Agents; Jurkat Cells; Leukocytes; Lipoproteins, LDL; Male; Membrane Glycoproteins; Middle Aged; Predictive Value of Tests; Regional Blood Flow; RNA, Messenger; Simvastatin; Tumor Necrosis Factors; Up-Regulation; Vasculitis | 2006 |
The reduction of inflammatory biomarkers by statin, fibrate, and combination therapy among diabetic patients with mixed dyslipidemia: the DIACOR (Diabetes and Combined Lipid Therapy Regimen) study.
Topics: Atherosclerosis; Biomarkers; C-Reactive Protein; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; Humans; Hypolipidemic Agents; Inflammation; Male; Middle Aged; Phospholipases A; Phospholipases A2; Simvastatin | 2006 |
Simvastatin attenuates plaque inflammation: evaluation by fluorodeoxyglucose positron emission tomography.
Topics: Aged; Aorta, Thoracic; Atherosclerosis; Carotid Stenosis; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Inflammation; Male; Middle Aged; Positron-Emission Tomography; Prospective Studies; Simvastatin | 2006 |
Simvastatin reduces plasma osteoprotegerin in type 2 diabetic patients with microalbuminuria.
Topics: Albuminuria; Atherosclerosis; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephropathies; Double-Blind Method; Enzyme-Linked Immunosorbent Assay; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Osteoprotegerin; Simvastatin | 2007 |
Intermittent doses of statin in hemodialysis patients with spontaneous low LDL cholesterol levels.
Topics: Adult; Aged; Anemia; Anticholesteremic Agents; Atherosclerosis; Biomarkers; C-Reactive Protein; Cholesterol, LDL; Drug Resistance; Erythropoietin; Female; Hemoglobins; Humans; Male; Malnutrition; Middle Aged; Nutritional Status; Prospective Studies; Renal Dialysis; Simvastatin; Young Adult | 2008 |
Simvastatin reduces circulating plasminogen activator inhibitor 1 activity in volunteers with the metabolic syndrome.
Topics: Anticholesteremic Agents; Atherosclerosis; Cardiovascular Diseases; CD40 Ligand; Cell Adhesion; Fibrinolysis; Humans; Inflammation; Ligands; Metabolic Syndrome; Models, Biological; P-Selectin; Placebos; Plasminogen Activator Inhibitor 1; Risk; Simvastatin | 2008 |
158 other study(ies) available for simvastatin and Atherogenesis
| Article | Year |
|---|---|
Novel benzoxazine and benzothiazine derivatives as multifunctional antihyperlipidemic agents.
Topics: Animals; Antioxidants; Atherosclerosis; Benzoxazines; Cholesterol, LDL; Farnesyl-Diphosphate Farnesyltransferase; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipid Peroxidation; Mice; Rats; Thiazines | 2011 |
New multifunctional Di-tert-butylphenoloctahydro(pyrido/benz)oxazine derivatives with antioxidant, antihyperlipidemic, and antidiabetic action.
Topics: Animals; Antioxidants; Atherosclerosis; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Farnesyl-Diphosphate Farnesyltransferase; Hyperlipidemias; Hypoglycemic Agents; Hypolipidemic Agents; Lipoproteins, LDL; Male; Mice; Oxidative Stress; Probucol; Rats | 2013 |
Design of novel potent antihyperlipidemic agents with antioxidant/anti-inflammatory properties: exploiting phenothiazine's strong antioxidant activity.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Atherosclerosis; Biphenyl Compounds; Carrageenan; Cholesterol, Dietary; Cyclooxygenase Inhibitors; Diet, High-Fat; Drug Design; Edema; Enzyme Inhibitors; Farnesyl-Diphosphate Farnesyltransferase; Hypolipidemic Agents; In Vitro Techniques; Indicators and Reagents; Lipid Peroxidation; Magnetic Resonance Spectroscopy; Male; Mice; Microsomes; Phenothiazines; Picrates; Rats | 2014 |
The effects of Rosmarinus officinalis L. essential oil and its nanoemulsion on dyslipidemic Wistar rats.
Topics: Animals; Atherosclerosis; Cholesterol, LDL; Dyslipidemias; Hypercholesterolemia; Hypertriglyceridemia; Nanoparticle Drug Delivery System; Oils, Volatile; Rats; Rats, Wistar; Rosmarinus; Simvastatin; Triglycerides | 2020 |
Renoprotective Effect of KLF2 on Glomerular Endothelial Dysfunction in Hypertensive Nephropathy.
Topics: Angiotensin II; Animals; Atherosclerosis; Endothelial Cells; Fibrosis; Humans; Hypertension, Renal; Interleukin-18; Kruppel-Like Transcription Factors; Mice; Nephritis; RNA, Messenger; Simvastatin; Transcription Factors | 2022 |
Anchoring β-CD on simvastatin-loaded rHDL for selective cholesterol crystals dissolution and enhanced anti-inflammatory effects in macrophage/foam cells.
Topics: Anti-Inflammatory Agents; Atherosclerosis; beta-Cyclodextrins; Cholesterol; Foam Cells; Humans; Inflammation; Lipoproteins, HDL; Macrophages; Plaque, Atherosclerotic; Simvastatin; Solubility | 2022 |
A ROS-Responsive Simvastatin Nano-Prodrug and its Fibronectin-Targeted Co-Delivery System for Atherosclerosis Treatment.
Topics: Animals; Atherosclerosis; Drug Liberation; Fibronectins; Mice; Nanoparticles; Prodrugs; Reactive Oxygen Species; Simvastatin; Ticagrelor | 2022 |
Establishment of a lipid metabolism disorder model in ApoEb mutant zebrafish.
Topics: Animals; Apolipoproteins E; Atherosclerosis; Ezetimibe; Hypercholesterolemia; Hyperlipidemias; Lipid Metabolism; Mammals; Simvastatin; Zebrafish | 2022 |
Xinmaikang (XMK) tablets alleviate atherosclerosis by regulating the SREBP2-mediated NLRP3/ASC/Caspase-1 signaling pathway.
Topics: Animals; Apolipoproteins E; Atherosclerosis; Body Weight; Caspase 1; Caspases; Cholesterol, LDL; Chromatography, Liquid; Interleukin-6; Mice; Mice, Knockout, ApoE; Molecular Docking Simulation; NLR Family, Pyrin Domain-Containing 3 Protein; Plaque, Atherosclerotic; Signal Transduction; Simvastatin; Tandem Mass Spectrometry; Tumor Necrosis Factor-alpha; Vascular Cell Adhesion Molecule-1 | 2024 |
Imaging-assisted nanoimmunotherapy for atherosclerosis in multiple species.
Topics: Animals; Apolipoproteins E; Atherosclerosis; Disease Models, Animal; Female; Imaging, Three-Dimensional; Immunotherapy; Lipoproteins, HDL; Magnetic Resonance Imaging; Male; Mice, Inbred C57BL; Nanomedicine; Positron-Emission Tomography; Rabbits; Simvastatin; Species Specificity; Swine; Tissue Distribution | 2019 |
U. diffracta extract mitigates high fat diet and VD3-induced atherosclerosis and biochemical changes in the serum liver and aorta of rats.
Topics: Animals; Aorta; Atherosclerosis; Calcium; Cytokines; Diet, High-Fat; Drugs, Chinese Herbal; Lipids; Liver; Models, Animal; Rats; Rats, Sprague-Dawley; Simvastatin; Usnea | 2019 |
Simvastatin mediates inhibition of exosome synthesis, localization and secretion via multicomponent interventions.
Topics: Animals; Asthma; Atherosclerosis; Cell Line; Cholesterol; Disease Models, Animal; Exosomes; Human Umbilical Vein Endothelial Cells; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Male; Mevalonic Acid; Mice; Mice, Inbred BALB C; Monocytes; Simvastatin | 2019 |
Application of a mechanically responsive, inflammatory macrophage-targeted dual-sensitive hydrogel drug carrier for atherosclerosis.
Topics: Animals; Atherosclerosis; Drug Carriers; Drug Delivery Systems; Hydrogels; Hypolipidemic Agents; Inflammation; Macrophages; Mice; Mice, Knockout; Micelles; Particle Size; Simvastatin; Surface Properties | 2020 |
Shuttle/sink model composed of β-cyclodextrin and simvastatin-loaded discoidal reconstituted high-density lipoprotein for enhanced cholesterol efflux and drug uptake in macrophage/foam cells.
Topics: Animals; Atherosclerosis; beta-Cyclodextrins; Cholesterol; Foam Cells; Hypolipidemic Agents; Lipoproteins, HDL; Macrophages; Mice; Models, Biological; Particle Size; RAW 264.7 Cells; Simvastatin; Surface Properties | 2020 |
A self-driven bioinspired nanovehicle by leukocyte membrane-hitchhiking for early detection and treatment of atherosclerosis.
Topics: Atherosclerosis; Humans; Inflammation; Leukocytes; Peptides; Simvastatin | 2020 |
Ziziphora clinopodioides flavonoids based on network pharmacology attenuates atherosclerosis in rats induced by high-fat emulsion combined with vitamin D
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Aorta; Aortic Diseases; Atherosclerosis; Cholecalciferol; Disease Models, Animal; Fat Emulsions, Intravenous; Flavonoids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lamiaceae; Lipids; Male; NF-kappa B; Oxidative Stress; Plant Extracts; Plaque, Atherosclerotic; Proto-Oncogene Proteins c-akt; Rats, Sprague-Dawley; Signal Transduction; Simvastatin; Vascular Endothelial Growth Factor A | 2020 |
Downregulation of lncRNA H19 alleviates atherosclerosis through inducing the apoptosis of vascular smooth muscle cells.
Topics: Animals; Apoptosis; Atherosclerosis; Cell Line; Cell Proliferation; Diet, High-Fat; Disease Models, Animal; Gene Knockdown Techniques; Humans; Male; Mice; Mice, Knockout, ApoE; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; RNA, Long Noncoding; Signal Transduction; Simvastatin; Up-Regulation | 2020 |
Hyaluronic acid-coated polymeric micelles with hydrogen peroxide scavenging to encapsulate statins for alleviating atherosclerosis.
Topics: Animals; Antioxidants; Atherosclerosis; Disease Models, Animal; Hyaluronic Acid; Hydrogen Peroxide; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Macrophages; Mice; Micelles; Oxidative Stress; Polyethylene Glycols; RAW 264.7 Cells; Simvastatin | 2020 |
Anti-inflammatory potential of simvastatin loaded nanoliposomes in 2D and 3D foam cell models.
Topics: Atherosclerosis; Cell Line; Drug Delivery Systems; Foam Cells; Humans; Inflammation; Liposomes; Nanoparticles; Plaque, Atherosclerotic; Simvastatin; Spheroids, Cellular | 2021 |
Effect of supplementation of Rhodomyrtus tomentosa fruit juice in preventing hypercholesterolemia and atherosclerosis development in rats fed with high fat high cholesterol diet.
Topics: Animals; Anticholesteremic Agents; Atherosclerosis; Cholesterol, Dietary; Diet, High-Fat; Dietary Supplements; Dose-Response Relationship, Drug; Fruit and Vegetable Juices; Hypercholesterolemia; Lipids; Male; Myrtaceae; Plant Extracts; Rats; Rats, Sprague-Dawley; Simvastatin | 2021 |
Effect of the treatment with Euterpe oleracea Mart. oil in rats with Triton-induced dyslipidemia.
Topics: Animals; Atherosclerosis; Cardiovascular Diseases; Cholesterol, HDL; Dyslipidemias; Euterpe; Hypolipidemic Agents; Lipids; Lipoproteins; Lipoproteins, LDL; Male; Plant Oils; Rats; Rats, Wistar; Simvastatin; Triglycerides | 2017 |
Downregulations of CD36 and Calpain-1, Inflammation, and Atherosclerosis by Simvastatin in Apolipoprotein E Knockout Mice.
Topics: Animals; Anti-Inflammatory Agents; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Aorta; Aortic Diseases; Apolipoproteins E; Atherosclerosis; Calpain; CD36 Antigens; Disease Models, Animal; Down-Regulation; Genetic Predisposition to Disease; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Inflammation Mediators; Interleukin-6; Lipoproteins, LDL; Male; Mice, Inbred C57BL; Mice, Knockout; Phenotype; Plaque, Atherosclerotic; Simvastatin; Thiobarbituric Acid Reactive Substances; Tumor Necrosis Factor-alpha | 2017 |
[Effects of simvastatin on aortic vascular endothelial cell apoptosis and Bcl-2 protein expression in a rat model of atherosclerosis].
Topics: Animals; Aorta; Apoptosis; Atherosclerosis; Endothelial Cells; Proto-Oncogene Proteins c-bcl-2; Random Allocation; Rats; Simvastatin | 2017 |
MicroRNA-100 Suppresses Chronic Vascular Inflammation by Stimulation of Endothelial Autophagy.
Topics: Animals; Atherosclerosis; Autophagy; Carotid Artery Diseases; Cell Adhesion Molecules; Cholesterol, LDL; Endothelial Cells; Human Umbilical Vein Endothelial Cells; Humans; Leukocytes; Macrophages; Male; Mice; Mice, Inbred C57BL; MicroRNAs; Receptors, LDL; Simvastatin; Specific Pathogen-Free Organisms; TOR Serine-Threonine Kinases; Transcriptome; Vasculitis | 2018 |
Sex disparity in the management and outcomes of dyslipidemia of diabetic patients in the Arabian Gulf: findings from the CEPHEUS study.
Topics: Adult; Aged; Atherosclerosis; Atorvastatin; Cholesterol, LDL; Diabetes Mellitus; Dyslipidemias; Female; Humans; Hypolipidemic Agents; Male; Middle Aged; Middle East; Rosuvastatin Calcium; Sex Characteristics; Simvastatin | 2018 |
Efficacy and Safety of Alirocumab in High-Risk Patients With Clinical Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia (from 5 Placebo-Controlled ODYSSEY Trials).
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Cholesterol, LDL; Clinical Trials, Phase III as Topic; Coronary Disease; Drug Therapy, Combination; Female; Heterozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipoproteinemia Type II; Male; Maximum Tolerated Dose; Middle Aged; PCSK9 Inhibitors; Peripheral Arterial Disease; Risk; Rosuvastatin Calcium; Simvastatin; Stroke; Treatment Outcome | 2018 |
A Mechano-Activated Cell Reporter System as a Proxy for Flow-Dependent Endothelial Atheroprotection.
Topics: Atherosclerosis; Endothelium, Vascular; Flow Cytometry; Gene Expression; Genes, Reporter; High-Throughput Screening Assays; Human Umbilical Vein Endothelial Cells; Humans; Kruppel-Like Transcription Factors; Mechanotransduction, Cellular; Microscopy, Fluorescence; Promoter Regions, Genetic; RNA, Small Interfering; Signal Transduction; Simvastatin; Stress, Mechanical | 2018 |
Effect of virgin avocado oil on diet-induced hypercholesterolemia in rats via
Topics: Animals; Atherosclerosis; Diet, High-Fat; Hypercholesterolemia; Lipids; Liver; Magnetic Resonance Spectroscopy; Male; Metabolomics; Non-alcoholic Fatty Liver Disease; Persea; Plant Oils; Rats; Rats, Sprague-Dawley; Simvastatin; Urinalysis | 2018 |
Fabrication of TPGS-Stabilized Liposome-PLGA Hybrid Nanoparticle Via a New Modified Nanoprecipitation Approach: In Vitro and In Vivo Evaluation.
Topics: Animals; Atherosclerosis; Drug Carriers; Drug Liberation; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liposomes; Mice; Nanoparticles; Oxidative Stress; Particle Size; Polylactic Acid-Polyglycolic Acid Copolymer; Rabbits; RAW 264.7 Cells; Simvastatin; Surface Properties; Vitamin E | 2018 |
Simultaneous LC-MS/MS analysis of simvastatin, atorvastatin, rosuvastatin and their active metabolites for plasma samples of obese patients underwent gastric bypass surgery.
Topics: Adult; Atherosclerosis; Atorvastatin; Calibration; Chromatography, High Pressure Liquid; Female; Gastric Bypass; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Obesity; Postoperative Period; Preoperative Period; Reproducibility of Results; Rosuvastatin Calcium; Simvastatin; Tandem Mass Spectrometry | 2019 |
Temporal trends, determinants, and impact of high-intensity statin prescriptions after percutaneous coronary intervention: Results from a large single-center prospective registry.
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Angina, Unstable; Atherosclerosis; Atorvastatin; Drug Prescriptions; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Non-ST Elevated Myocardial Infarction; Odds Ratio; Percutaneous Coronary Intervention; Practice Guidelines as Topic; Prospective Studies; Registries; Rosuvastatin Calcium; Secondary Prevention; Simvastatin; ST Elevation Myocardial Infarction; Tertiary Care Centers; Time Factors | 2019 |
Onset timing of statin-induced musculoskeletal adverse events and concomitant drug-associated shift in onset timing of MAEs.
Topics: Adverse Drug Reaction Reporting Systems; Atherosclerosis; Atorvastatin; Cholesterol, LDL; Drug Interactions; Drug Therapy, Combination; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Musculoskeletal Diseases; Rosuvastatin Calcium; Simvastatin; Time Factors; United States; United States Food and Drug Administration | 2018 |
Si-Miao-Yong-An on promoting the maturation of Vasa Vasorum and stabilizing atherosclerotic plaque in ApoE
Topics: Animals; Apolipoproteins E; Atherosclerosis; Drugs, Chinese Herbal; Male; Mice; Mice, Inbred C57BL; Neovascularization, Pathologic; Plaque, Atherosclerotic; Simvastatin; Vasa Vasorum | 2019 |
Naoxintong protects against atherosclerosis through lipid-lowering and inhibiting maturation of dendritic cells in LDL receptor knockout mice fed a high-fat diet.
Topics: Animals; Atherosclerosis; Body Weight; Cytokines; Dendritic Cells; Diet, High-Fat; Drugs, Chinese Herbal; Hypolipidemic Agents; Lipids; Male; Mice; Mice, Knockout; Receptors, LDL; Simvastatin | 2013 |
Simvastatin suppresses vascular inflammation and atherosclerosis in ApoE(-/-) mice by downregulating the HMGB1-RAGE axis.
Topics: Animals; Aorta; Apolipoproteins E; Atherosclerosis; Blotting, Western; Down-Regulation; HMGB1 Protein; Human Umbilical Vein Endothelial Cells; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Macrophages; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Receptor for Advanced Glycation End Products; Receptors, Immunologic; Simvastatin | 2013 |
2,3,4',5-tetrahydroxystilbene-2-O-β-D-glucoside suppresses expression of adhesion molecules in aortic wall of dietary atherosclerotic rats and promonocytic U937 cells.
Topics: Animals; Aorta; Atherosclerosis; Cell Adhesion Molecules; Diet, High-Fat; Gene Expression Regulation; Glucosides; Humans; Intercellular Adhesion Molecule-1; Lipoproteins, LDL; Male; Monocyte-Macrophage Precursor Cells; Rats; Rats, Sprague-Dawley; RNA, Messenger; Simvastatin; Stilbenes; U937 Cells; Vascular Cell Adhesion Molecule-1 | 2013 |
Niacin Reduces Atherosclerosis Development in APOE*3Leiden.CETP Mice Mainly by Reducing NonHDL-Cholesterol.
Topics: Animals; Apolipoprotein E3; Atherosclerosis; Biological Transport; Cholesterol; Cholesterol Ester Transfer Proteins; Female; Gene Expression; Liver; Mice; Mice, Transgenic; Niacin; RNA, Messenger; Simvastatin; Triglycerides | 2013 |
Anti-atherogenic effects of statins: Impact on angiopoietin-2 release from endothelial cells.
Topics: Acyl Coenzyme A; Angiopoietin-2; Atherosclerosis; Cell Survival; Cells, Cultured; Endothelial Cells; Exocytosis; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Nitric Oxide; Nitric Oxide Synthase Type III; Pravastatin; Simvastatin; Weibel-Palade Bodies | 2013 |
Serum levels of cytokines and chemokines associated with cardiovascular disease in Brazilian patients treated with statins for dyslipidemia.
Topics: Adult; Aged; Atherosclerosis; Brazil; Cardiovascular Diseases; Chemokine CCL2; Chemokine CXCL9; Chemokines; Cytokines; Dyslipidemias; Female; Gene Expression Regulation; Humans; Male; Middle Aged; Simvastatin; Treatment Outcome; Young Adult | 2014 |
Antihyperlipidemic and antiatherogenic activity of simvastatin may involve modulation of the expression of lecithin:cholesterol acyl transferase.
Topics: Animals; Atherosclerosis; Gene Expression Regulation, Enzymologic; Humans; Hypolipidemic Agents; Lipoproteins, HDL; Lipoproteins, LDL; Phosphatidylcholine-Sterol O-Acyltransferase; Rats; Simvastatin | 2013 |
The combination of L-4F and simvastatin stimulate cholesterol efflux and related proteins expressions to reduce atherosclerotic lesions in apoE knockout mice.
Topics: Animals; Apolipoprotein A-I; Apolipoproteins E; Atherosclerosis; ATP Binding Cassette Transporter 1; ATP Binding Cassette Transporter, Subfamily G, Member 1; ATP-Binding Cassette Transporters; Biological Transport; Cholesterol; Cholesterol, LDL; Drug Therapy, Combination; Gene Expression; Hypolipidemic Agents; Lipoproteins; Liver X Receptors; Male; Mice; Mice, Knockout; Molecular Mimicry; Orphan Nuclear Receptors; Peptides; Plaque, Atherosclerotic; PPAR gamma; Scavenger Receptors, Class B; Simvastatin | 2013 |
Effects of simvastatin on retinal structure and function of a high-fat atherogenic mouse model of thickened Bruch's membrane.
Topics: Animals; Anticholesteremic Agents; Atherosclerosis; Bruch Membrane; Disease Models, Animal; Electroretinography; Follow-Up Studies; Macular Degeneration; Mice; Mice, Inbred C57BL; Microscopy, Electron, Transmission; Pigment Epithelium of Eye; Simvastatin; Treatment Outcome | 2014 |
Statin treatment is associated with reduction in serum levels of receptor activator of NF-κB ligand and neutrophil activation in patients with severe carotid stenosis.
Topics: Aged; Atherosclerosis; Atorvastatin; Carotid Stenosis; Cohort Studies; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Matrix Metalloproteinase 9; Middle Aged; Neutrophil Activation; Neutrophils; NF-kappa B; Osteopontin; Osteoprotegerin; Pyrimidines; Pyrroles; RANK Ligand; Risk Factors; RNA, Messenger; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2014 |
Statin-induced impairment of monocyte migration is gender-related.
Topics: Atherosclerosis; Atorvastatin; Cell Movement; Female; Healthy Volunteers; Heptanoic Acids; Humans; Inflammation; Lipopolysaccharides; Male; Monocytes; Pyrroles; Sex Characteristics; Simvastatin; Tumor Necrosis Factor-alpha | 2014 |
Evaluation of antihyperlipidemic potency of a polyherbomineral formulation (AF-LIP) in experimental animal models.
Topics: Acyl Coenzyme A; Animals; Atherosclerosis; Cholesterol; Diet, High-Fat; Dose-Response Relationship, Drug; Feces; Female; Fenofibrate; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins; Male; Plant Extracts; Polyethylene Glycols; Rats; Rats, Wistar; Simvastatin | 2014 |
Endoplasmic reticulum stress effector CCAAT/enhancer-binding protein homologous protein (CHOP) regulates chronic kidney disease-induced vascular calcification.
Topics: Animals; Apolipoproteins E; Atherosclerosis; Azetidines; Calcinosis; Cardiovascular Diseases; Case-Control Studies; Drug Therapy, Combination; Endoplasmic Reticulum; Ezetimibe; Humans; Ketocholesterols; Lipids; Male; Mice, Inbred C57BL; Mice, Knockout; Middle Aged; Renal Insufficiency, Chronic; Simvastatin; Transcription Factor CHOP; Vascular Diseases | 2014 |
[Effect of simvastatin on atherosclerosis and central aortic pressure in ApoE gene knockout mice].
Topics: Animals; Apolipoproteins E; Arterial Pressure; Atherosclerosis; Cholesterol; Disease Models, Animal; Lipoproteins, HDL; Lipoproteins, LDL; Male; Mice; Mice, Knockout; Simvastatin; Triglycerides | 2014 |
Trends in use of ezetimibe after the ENHANCE trial, 2007 through 2010.
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Atherosclerosis; Azetidines; Clinical Trials as Topic; Disease Progression; Ezetimibe; Female; Humans; Hypercholesterolemia; Insurance, Pharmaceutical Services; Male; Middle Aged; Retrospective Studies; Simvastatin; Treatment Outcome; United States | 2014 |
Antiatherosclerotic Potential of Rhizoma Polygonati Polysaccharide in Hyperlipidemia-induced Atherosclerotic Hamsters.
Topics: Animals; Aorta; Apolipoproteins; Atherosclerosis; Cricetinae; Diet, Atherogenic; Dose-Response Relationship, Drug; Drugs, Chinese Herbal; Hyperlipidemias; Lipids; Male; Polygonatum; Polysaccharides; Simvastatin | 2015 |
[Neurological disturbances in patient who ingested high doses of simvastatin].
Topics: Atherosclerosis; Cognition Disorders; Drug Overdose; Dyslipidemias; Electromagnetic Fields; Humans; Male; Memory Disorders; Middle Aged; Occupational Diseases; Simvastatin; Sleep Wake Disorders | 2014 |
Effect of pioglitazone combined with simvastatin on the CD40-CD40 ligand system in rabbits with atherosclerosis.
Topics: Animals; Atherosclerosis; CD40 Antigens; CD40 Ligand; Hypolipidemic Agents; Lipids; Male; Pioglitazone; Rabbits; Random Allocation; Simvastatin; Thiazolidinediones | 2015 |
The antiatherogenic effect of bixin in hypercholesterolemic rabbits is associated to the improvement of lipid profile and to its antioxidant and anti-inflammatory effects.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Aorta; Atherosclerosis; Body Weight; Carotenoids; Hypercholesterolemia; Lipids; Male; Oxidation-Reduction; Plaque, Atherosclerotic; Rabbits; Simvastatin; Sulfhydryl Compounds; Thiobarbituric Acid Reactive Substances; Tumor Necrosis Factor-alpha; Tunica Intima | 2015 |
Captopril inhibits maturation of dendritic cells and maintains their tolerogenic property in atherosclerotic rats.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antigens, CD; Aorta; Atherosclerosis; Captopril; Cholesterol; Cytokines; Dendritic Cells; Diet, Atherogenic; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Flow Cytometry; Lipids; Male; Rats, Sprague-Dawley; Simvastatin; T-Lymphocytes, Regulatory | 2015 |
Molecular hydrogen stabilizes atherosclerotic plaque in low-density lipoprotein receptor-knockout mice.
Topics: Animals; Apoptosis; Atherosclerosis; Disease Models, Animal; Endoplasmic Reticulum Stress; Humans; Hydrogen; Macrophages; Mice; Mice, Knockout; NF-E2-Related Factor 2; Plaque, Atherosclerotic; Reactive Oxygen Species; Receptors, LDL; Receptors, Oxidized LDL; Simvastatin | 2015 |
Comparison of the effects of hypolipidemic treatment on monocyte proinflammatory cytokine release in men and women with type 2 diabetes and atherogenic dyslipidemia.
Topics: Atherosclerosis; C-Reactive Protein; Cytokines; Diabetes Mellitus, Type 2; Dyslipidemias; Female; Fenofibrate; Humans; Hypolipidemic Agents; Male; Middle Aged; Monocytes; Sex Factors; Simvastatin | 2015 |
Icariin Attenuates High-cholesterol Diet Induced Atherosclerosis in Rats by Inhibition of Inflammatory Response and p38 MAPK Signaling Pathway.
Topics: Animals; Anticholesteremic Agents; Atherosclerosis; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diet, High-Fat; Disease Models, Animal; Down-Regulation; Drugs, Chinese Herbal; Dyslipidemias; Flavonoids; Inflammation; Interleukin-6; Lipids; Male; Malondialdehyde; MAP Kinase Signaling System; Oxidative Stress; p38 Mitogen-Activated Protein Kinases; Rats; Rats, Wistar; RNA, Messenger; Simvastatin; Superoxide Dismutase; Triglycerides; Tumor Necrosis Factor-alpha | 2016 |
Antihypercholesterolemic and antioxidant efficacies of zerumbone on the formation, development, and establishment of atherosclerosis in cholesterol-fed rabbits.
Topics: Animals; Anticholesteremic Agents; Antioxidants; Aorta; Aortic Diseases; Atherosclerosis; Biomarkers; Cholesterol, Dietary; Dietary Supplements; Disease Models, Animal; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Malondialdehyde; Oxidative Stress; Plaque, Atherosclerotic; Rabbits; Sesquiterpenes; Simvastatin; Superoxide Dismutase; Time Factors | 2015 |
Inhibition of Atherosclerosis Progression, Intimal Hyperplasia, and Oxidative Stress by Simvastatin and Ivabradine May Reduce Thoracic Aorta's Stiffness in Hypercholesterolemic Rabbits.
Topics: Animals; Antioxidants; Aorta, Thoracic; Aortic Diseases; Atherosclerosis; Benzazepines; Diet, Atherogenic; Disease Models, Animal; Disease Progression; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperplasia; Ivabradine; Male; Neointima; Oxidative Stress; Plaque, Atherosclerotic; Rabbits; Simvastatin; Vascular Stiffness | 2016 |
Considerations in Applying the Results of Randomized Controlled Clinical Trials to the Care of Older Adults With Kidney Disease in the Clinical Setting: The SHARP Trial.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anticholesteremic Agents; Atherosclerosis; Clinical Decision-Making; Drug Administration Schedule; Drug Therapy, Combination; Ezetimibe; Female; Health Services for the Aged; Humans; Male; Middle Aged; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Renal Dialysis; Renal Insufficiency, Chronic; Risk Factors; Simvastatin | 2016 |
Antioxidation Effect of Simvastatin in Aorta and Hippocampus: A Rabbit Model Fed High-Cholesterol Diet.
Topics: Animals; Antioxidants; Aorta; Atherosclerosis; Diet, High-Fat; Disease Models, Animal; Heme Oxygenase-1; Hippocampus; Immunohistochemistry; Male; Oxidative Stress; Rabbits; RNA, Messenger; Simvastatin | 2016 |
Antihyperlipidemic Effect of Syrian Mesquite (Prosopis farcta) Root in High Cholesterol Diet-Fed Rabbits.
Topics: Animals; Aorta; Atherosclerosis; Cholesterol; Diet, High-Fat; Hypolipidemic Agents; Male; Plant Extracts; Plant Roots; Prosopis; Rabbits; Simvastatin | 2016 |
[Effect of Buyang Huanwu Decoction on mRNA Expressions of Aorta Rho Kinase and NF-κB p65 in Atherosclerosis Model Rats].
Topics: Animals; Aorta; Atherosclerosis; Drugs, Chinese Herbal; Gene Expression; Lipids; Lipoproteins, LDL; NF-kappa B; Rats; rho-Associated Kinases; RNA, Messenger; Simvastatin; Transcription Factor RelA | 2015 |
The effect of hypolipidemic treatment on monocyte cytokine release in different age groups of patients with type 2 diabetes and atherogenic dyslipidemia.
Topics: Adult; Age Factors; Aged; Atherosclerosis; Cytokines; Diabetes Mellitus, Type 2; Dyslipidemias; Female; Fenofibrate; Humans; Hypolipidemic Agents; Male; Middle Aged; Monocytes; Retrospective Studies; Simvastatin; Treatment Outcome; Young Adult | 2016 |
Multiple pathway assessment to predict anti-atherogenic efficacy of drugs targeting macrophages in atherosclerotic plaques.
Topics: Animals; Anti-Inflammatory Agents; Atherosclerosis; Cell Proliferation; Cytokines; Endoplasmic Reticulum Stress; High-Throughput Screening Assays; Humans; Hydrocarbons, Fluorinated; Inflammation; Inflammation Mediators; Lipid Metabolism; Lipopolysaccharides; Macrophage Activation; Macrophages; Mice; Mice, Inbred C57BL; NF-kappa B; Oxidative Stress; Plaque, Atherosclerotic; Prednisolone; RAW 264.7 Cells; Reactive Oxygen Species; Signal Transduction; Simvastatin; Stilbenes; Sulfonamides; Transfection | 2016 |
Simvastatin-loaded nanostructured lipid carriers attenuate the atherogenic risk of erythrocytes in hyperlipidemic rats.
Topics: Animals; Atherosclerosis; Drug Carriers; Drug Liberation; Erythrocytes; Female; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Kidney; Lipid Metabolism; Lipids; Liver; Nanostructures; Rats; Risk; Simvastatin | 2017 |
Simvastatin inhibited oxLDL-induced proatherogenic effects through calpain-1-PPARγ-CD36 pathway.
Topics: Animals; Atherosclerosis; Calpain; CD36 Antigens; Cells, Cultured; Humans; Lipoproteins, LDL; Macrophages; Mice; PPAR gamma; Signal Transduction; Simvastatin | 2016 |
Anti-atherosclerosis and cardio-protective effects of the Angong Niuhuang Pill on a high fat and vitamin D3 induced rodent model of atherosclerosis.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Aorta, Thoracic; Aortic Diseases; Apoptosis; Atherosclerosis; Biomarkers; Carotid Artery Diseases; Cholecalciferol; Diet, High-Fat; Disease Models, Animal; Drugs, Chinese Herbal; Enzymes; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Inflammation Mediators; Lipids; Male; Myocardium; Platelet Aggregation; Platelet Aggregation Inhibitors; Rats, Sprague-Dawley; Simvastatin; Tablets; Time Factors | 2017 |
Simvastatin inhibits homocysteine-induced CRP generation via interfering with the ROS-p38/ERK1/2 signal pathway in rat vascular smooth muscle cells.
Topics: Animals; Anti-Inflammatory Agents; Atherosclerosis; C-Reactive Protein; Cells, Cultured; Dose-Response Relationship, Drug; Homocysteine; Inflammation; Male; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; p38 Mitogen-Activated Protein Kinases; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Risk Factors; Signal Transduction; Simvastatin | 2017 |
Progression and Characterization of the Accelerated Atherosclerosis in Iliac Artery of New Zealand White Rabbits: Effect of Simvastatin.
Topics: Angioplasty, Balloon; Animals; Atherosclerosis; Biomarkers; Diet, High-Fat; Disease Models, Animal; Disease Progression; Endothelium, Vascular; Extracellular Matrix; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Iliac Artery; Inflammation Mediators; Lipids; Macrophages; Male; Plaque, Atherosclerotic; Rabbits; Simvastatin; Time Factors; Vascular Remodeling; Vasoconstriction; Vasodilation | 2017 |
Soy milk versus simvastatin for preventing atherosclerosis and left ventricle remodeling in LDL receptor knockout mice.
Topics: Animals; Anticholesteremic Agents; Atherosclerosis; Diet; Male; Mice; Mice, Knockout; Receptors, LDL; Simvastatin; Soy Milk; Ventricular Remodeling | 2017 |
The anti-osteoporotic and anti-atherogenic effects of alendronate and simvastatin in ovariectomized rats fed high fat diet: A comparative study of combination therapy versus monotherapy.
Topics: Alendronate; Alkaline Phosphatase; Animals; Atherosclerosis; Body Weight; Bone and Bones; Bone Density; Combined Modality Therapy; Diet, High-Fat; Female; Osteocalcin; Osteoporosis; Ovariectomy; Rats; Simvastatin | 2017 |
Emodin promotes atherosclerotic plaque stability in fat-fed apolipoprotein E-deficient mice.
Topics: Animals; Apolipoproteins E; Atherosclerosis; Dietary Fats; Emodin; Growth Inhibitors; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Simvastatin | 2008 |
The implications of the ezetimibe and simvastatin in hypercholesterolemia enhances atherosclerosis regression trial: a return to first principles.
Topics: Anticholesteremic Agents; Atherosclerosis; Azetidines; Cholesterol; Clinical Trials as Topic; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Simvastatin; Treatment Outcome | 2008 |
Is it over for ezetimibe?
Topics: Anticholesteremic Agents; Atherosclerosis; Azetidines; Controlled Clinical Trials as Topic; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Simvastatin | 2008 |
Rosiglitazone promotes atherosclerotic plaque stability in fat-fed ApoE-knockout mice.
Topics: Animals; Apolipoproteins E; Atherosclerosis; Cholesterol; Dietary Fats; Granulocyte-Macrophage Colony-Stimulating Factor; Hypoglycemic Agents; Male; Matrix Metalloproteinase 9; Mice; Mice, Inbred C57BL; Mice, Knockout; PPAR gamma; Rosiglitazone; Simvastatin; Thiazolidinediones | 2008 |
Simvastatin, an inhibitor of epithelial-to-mesenchymal transition in experimental atherosclerotic renovascular disease?
Topics: Animals; Atherosclerosis; Epithelial Cells; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension, Renal; Mesenchymal Stem Cells; Simvastatin | 2008 |
Simvastatin abates development of renal fibrosis in experimental renovascular disease.
Topics: Animals; Atherosclerosis; Blood Pressure; Disease Models, Animal; Epithelial Cells; Fibrosis; Glomerular Filtration Rate; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension, Renal; Mesenchymal Stem Cells; Renal Artery Obstruction; Renal Circulation; Simvastatin; Sus scrofa | 2008 |
Attenuation of inflammation and expansive remodeling by Valsartan alone or in combination with Simvastatin in high-risk coronary atherosclerotic plaques.
Topics: Animals; Antihypertensive Agents; Atherosclerosis; Blood Pressure; Coronary Artery Disease; Disease Models, Animal; Endothelium, Vascular; Inflammation; Lipids; Male; Rabbits; Risk; Simvastatin; Stress, Mechanical; Tetrazoles; Valine; Valsartan | 2009 |
After ENHANCE: the cholesterol hypothesis is alive and well.
Topics: Anticholesteremic Agents; Atherosclerosis; Azetidines; Ezetimibe; Humans; Hypercholesterolemia; Randomized Controlled Trials as Topic; Simvastatin; Tunica Intima; Tunica Media; Ultrasonography | 2008 |
[Simvastatin effects on the disease activity and cholesterol content in blood serum lipoprotein subfractions in patients with rheumatoid arthritis].
Topics: Adult; Aged; Anticholesteremic Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Atherosclerosis; Cholesterol; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Lipoproteins; Male; Middle Aged; Pilot Projects; Simvastatin; Treatment Outcome | 2008 |
Is carotid intima-media thickness a reliable clinical predictor?
Topics: Anticholesteremic Agents; Atherosclerosis; Azetidines; Carotid Arteries; Carotid Artery Diseases; Coronary Disease; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Simvastatin; Tunica Intima; Tunica Media | 2008 |
Calcific aortic stenosis.
Topics: Animals; Anticholesteremic Agents; Aortic Valve Stenosis; Atherosclerosis; Azetidines; Calcinosis; Disease Progression; Ezetimibe; Humans; Models, Biological; Renal Insufficiency, Chronic; Simvastatin | 2009 |
Effects of probiotic bacteria, isoflavones and simvastatin on lipid profile and atherosclerosis in cholesterol-fed rabbits: a randomized double-blind study.
Topics: Animals; Aorta; Atherosclerosis; Cholesterol; Diet; Dietary Fats; Enterococcus faecium; Isoflavones; Male; Organ Size; Probiotics; Rabbits; Random Allocation; Simvastatin; Weight Gain | 2009 |
Ezetimibe reduces plaque inflammation in a rabbit model of atherosclerosis and inhibits monocyte migration in addition to its lipid-lowering effect.
Topics: Animals; Anticholesteremic Agents; Atherosclerosis; Azetidines; C-Reactive Protein; Cell Line; Cell Movement; Chemokine CCL2; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Therapy, Combination; Ezetimibe; Femoral Artery; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Inflammation Mediators; Lipids; Macrophages; Male; Monocytes; NF-kappa B; Rabbits; Simvastatin | 2009 |
Anti-atherogenic effect of statins: role of nitric oxide, peroxynitrite and haem oxygenase-1.
Topics: Animals; Aorta; Arginine; Atherosclerosis; Atorvastatin; Disease Models, Animal; Endothelium, Vascular; Enzyme Inhibitors; Heme Oxygenase-1; Hemin; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Peroxidation; Male; Malondialdehyde; Metalloporphyrins; NG-Nitroarginine Methyl Ester; Nitric Oxide; Nitric Oxide Synthase Type III; Peroxynitrous Acid; Protoporphyrins; Pyrroles; Rabbits; Simvastatin; Time Factors | 2009 |
Simvastatin inhibits sPLA2 IIa expression in aorta and myocardium.
Topics: Animals; Anticholesteremic Agents; Aorta; Atherosclerosis; Cholesterol; Gene Expression; Group II Phospholipases A2; Intra-Abdominal Fat; Male; Myocardium; Myocytes, Smooth Muscle; Rats; Rats, Wistar; Simvastatin; Triglycerides | 2009 |
Statins normalize vascular lysyl oxidase down-regulation induced by proatherogenic risk factors.
Topics: Animals; Atherosclerosis; Atorvastatin; Capillary Permeability; Cattle; Cells, Cultured; Disease Models, Animal; Diterpenes; Dose-Response Relationship, Drug; Down-Regulation; Endothelial Cells; Farnesol; Female; Gene Expression Regulation, Enzymologic; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipoproteins, LDL; Protein Kinase C; Protein Kinase Inhibitors; Protein-Lysine 6-Oxidase; Pyrroles; rho-Associated Kinases; rhoA GTP-Binding Protein; Risk Factors; RNA, Messenger; Simvastatin; Swine; Transfection; Tumor Necrosis Factor-alpha | 2009 |
Anti-atherogenic effects of centipede acidic protein in rats fed an atherogenic diet.
Topics: Acids; Animals; Anticholesteremic Agents; Aorta; Arthropods; Atherosclerosis; Diet, Atherogenic; Disease Models, Animal; Endothelin-1; Hemorheology; Hypolipidemic Agents; Lipid Peroxidation; Lipids; Male; Malondialdehyde; Medicine, Chinese Traditional; Nitric Oxide; Proteins; Rats; Rats, Sprague-Dawley; Simvastatin; Superoxide Dismutase | 2009 |
Shear stress preconditioning modulates endothelial susceptibility to circulating TNF-alpha and monocytic cell recruitment in a simplified model of arterial bifurcations.
Topics: Anti-Inflammatory Agents; Atherosclerosis; Cell Adhesion; Cell Culture Techniques; Cells, Cultured; Computer Simulation; E-Selectin; Endothelial Cells; Fluorescent Antibody Technique; Humans; Models, Cardiovascular; Monocytes; NF-kappa B; Numerical Analysis, Computer-Assisted; Resveratrol; Simvastatin; Stilbenes; Stress, Mechanical; Stress, Physiological; Time Factors; Tumor Necrosis Factor-alpha; Vascular Cell Adhesion Molecule-1 | 2009 |
Antidiabetic effects of 11beta-HSD1 inhibition in a mouse model of combined diabetes, dyslipidaemia and atherosclerosis.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Adipose Tissue; Animals; Atherosclerosis; Blood Glucose; Body Composition; Body Weight; Cholesterol; Diabetes Mellitus, Type 2; Disease Models, Animal; Dyslipidemias; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Insulin; Male; Metabolic Syndrome; Mice; Mice, Knockout; Rosiglitazone; Simvastatin; Thiazolidinediones; Triglycerides | 2009 |
Aortic stenosis: look globally, think globally.
Topics: Aortic Valve Stenosis; Atherosclerosis; Azetidines; Calcinosis; Disease Progression; Drug Combinations; Echocardiography, Doppler; Ezetimibe, Simvastatin Drug Combination; Hemodynamics; Humans; Hypolipidemic Agents; Myocardial Contraction; Predictive Value of Tests; Risk Assessment; Risk Factors; Simvastatin; Systole; Treatment Outcome; Ventricular Dysfunction, Left | 2009 |
Antiatherogenic effect of simvastatin is not due to decrease of LDL cholesterol in ovariectomized golden Syrian hamster.
Topics: Animals; Aorta, Abdominal; Aorta, Thoracic; Aortic Diseases; Atherosclerosis; Biomarkers; Cholesterol, HDL; Cholesterol, LDL; Cricetinae; Disease Models, Animal; Drug Administration Schedule; Female; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, LDL; Mesocricetus; Ovariectomy; Simvastatin; Time Factors; Triglycerides | 2010 |
Effects of simvastatin on plasma lipoproteins and hearing loss in apolipoprotein E gene-deficient mice.
Topics: Animals; Anticholesteremic Agents; Apolipoproteins E; Atherosclerosis; Female; Hair Cells, Auditory; Hearing Loss, Sensorineural; Hyperlipidemias; Lipids; Mice; Mice, Inbred C57BL; Mice, Knockout; Severity of Illness Index; Simvastatin | 2009 |
Atherosclerosis regression study in rabbits upon olive pomace polar lipid extract administration.
Topics: Analysis of Variance; Animals; Atherosclerosis; Cholesterol; Diet, Atherogenic; Dietary Supplements; Disease Models, Animal; Dyslipidemias; Male; Olea; Olive Oil; Plant Oils; Platelet Aggregation; Rabbits; Regression Analysis; Simvastatin | 2010 |
Ezetimibe - new anti-atherogenic properties?
Topics: Animals; Anticholesteremic Agents; Atherosclerosis; Azetidines; C-Reactive Protein; Cell Movement; Chemokine CCL2; Disease Models, Animal; Drug Therapy, Combination; Ezetimibe; Femoral Artery; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Inflammation Mediators; Lipids; Macrophages; Monocytes; NF-kappa B; Rabbits; Simvastatin | 2009 |
Traditional Chinese medication Tongxinluo dose-dependently enhances stability of vulnerable plaques: a comparison with a high-dose simvastatin therapy.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Aortic Diseases; Aortic Rupture; Atherosclerosis; Biomarkers; Catheterization; Disease Models, Animal; Disease Progression; Dose-Response Relationship, Drug; Drugs, Chinese Herbal; Gene Expression Regulation; Gene Transfer Techniques; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Immunohistochemistry; Inflammation Mediators; Lipids; Male; Rabbits; RNA, Messenger; Simvastatin; Time Factors; Tumor Suppressor Protein p53; Ultrasonography, Doppler, Duplex; Ultrasonography, Interventional; Viper Venoms | 2009 |
The challenge of traditional Chinese medicines for allopathic practitioners.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Aortic Diseases; Aortic Rupture; Atherosclerosis; Biomarkers; Cardiovascular Agents; Complementary Therapies; Disease Progression; Drugs, Chinese Herbal; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation Mediators; Lipids; Simvastatin | 2009 |
A study of the comparative effects of hawthorn fruit compound and simvastatin on lowering blood lipid levels.
Topics: Actinidia; Animals; Anticholesteremic Agents; Apolipoproteins E; Atherosclerosis; Cholesterol; Cholesterol, Dietary; Cholesterol, HDL; Cholesterol, LDL; Crataegus; Drug Therapy, Combination; Fruit; Lipids; Mice; Mice, Knockout; Phytotherapy; Plant Extracts; Random Allocation; Simvastatin; Triglycerides | 2009 |
A macrophage sterol-responsive network linked to atherogenesis.
Topics: Animals; Apolipoproteins E; Atherosclerosis; Foam Cells; Gene Expression Regulation; Hypoglycemic Agents; Hypolipidemic Agents; Macrophages; Male; Mice; Mice, Inbred C57BL; Proteins; Receptors, LDL; Rosiglitazone; Simvastatin; Sterols; Thiazolidinediones | 2010 |
Multiplex coherent anti-stokes Raman spectroscopy images intact atheromatous lesions and concomitantly identifies distinct chemical profiles of atherosclerotic lipids.
Topics: Animals; Aorta; Apolipoproteins E; Atherosclerosis; Azo Compounds; Brachiocephalic Trunk; Coloring Agents; Crystallization; Disease Models, Animal; Disease Progression; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Image Processing, Computer-Assisted; Immunohistochemistry; Lipid Metabolism; Lipids; Male; Mice; Mice, Knockout; Microspectrophotometry; Molecular Structure; Reproducibility of Results; Simvastatin; Spectrum Analysis, Raman; Staining and Labeling; Time Factors | 2010 |
[The effect of simvastatin on the expression of high mobility group box-1 protein in atherosclerotic rats].
Topics: Animals; Atherosclerosis; Disease Models, Animal; HMGB1 Protein; Male; Plaque, Atherosclerotic; Random Allocation; Rats; Rats, Wistar; RNA, Messenger; Simvastatin | 2010 |
Reduction of endoplasmic reticulum stress--a novel mechanism of action of statins in the protection against atherosclerosis.
Topics: Animals; Antigens, Differentiation; Atherosclerosis; Cell Line; Disease Models, Animal; DNA-Binding Proteins; eIF-2 Kinase; Endoplasmic Reticulum; Endoplasmic Reticulum Chaperone BiP; Eukaryotic Initiation Factor-2; Fatty Acids; Heat-Shock Proteins; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Macrophages; Mice; Mice, Knockout; Phosphorylation; Pravastatin; Receptors, LDL; Regulatory Factor X Transcription Factors; Simvastatin; Stress, Physiological; Transcription Factors | 2010 |
[Should the treatment of diabetic dyslipidemia be modified after the Action to Control Cardiovascular Risk in Diabetes Lipid study?].
Topics: Aged; Atherosclerosis; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Male; Middle Aged; Multicenter Studies as Topic; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Simvastatin | 2010 |
Managing residual risk in patients receiving statin therapy.
Topics: Anticholesteremic Agents; Atherosclerosis; Azetidines; Cholesterol, LDL; Ezetimibe; Humans; Hypercholesterolemia; Simvastatin | 2010 |
Laminar shear stress prevents simvastatin-induced adhesion molecule expression in cytokine activated endothelial cells.
Topics: Anticholesteremic Agents; Aorta, Abdominal; Atherosclerosis; Blotting, Western; Cell Adhesion Molecules; Cell Line; Cytokines; Endothelium, Vascular; Gene Expression Regulation; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intercellular Adhesion Molecule-1; Mevalonic Acid; Osmolar Concentration; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Simvastatin; Stress, Mechanical; Tumor Necrosis Factor-alpha; Vascular Cell Adhesion Molecule-1 | 2010 |
Effect of Qingre Quyu Granule (清热祛瘀颗粒) on stabilizing plaques in the brachiocephalic artery of apolipoprotein E deficient mice.
Topics: Animals; Apolipoproteins E; Atherosclerosis; Brachiocephalic Trunk; Drugs, Chinese Herbal; Enzyme-Linked Immunosorbent Assay; Intercellular Adhesion Molecule-1; Male; Matrix Metalloproteinase 9; Mice; Mice, Knockout; NF-kappa B; Reverse Transcriptase Polymerase Chain Reaction; Simvastatin; Sodium Chloride; Thrombospondin 1 | 2010 |
Emphasizing the burden of proof: The American College of Cardiology 2008 Expert Panel Comments on the ENHANCE Trial.
Topics: Anticholesteremic Agents; Atherosclerosis; Azetidines; Biomarkers; Cardiology; Carotid Arteries; Clinical Trials as Topic; Clinical Trials Data Monitoring Committees; Evidence-Based Medicine; Expert Testimony; Ezetimibe; Humans; Hypercholesterolemia; Lipoproteins, LDL; Simvastatin | 2010 |
The effects of simvastatin on angiogenesis: studied by an original model of atherosclerosis and acute myocardial infarction in rabbit.
Topics: Animals; Aorta, Thoracic; Atherosclerosis; Coronary Angiography; Disease Models, Animal; Heart Function Tests; Hypoxia-Inducible Factor 1, alpha Subunit; Immunohistochemistry; Lipids; Male; Myocardial Infarction; Neovascularization, Pathologic; Rabbits; Simvastatin; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2011 |
OxLDL-dependent activation of arginase II is dependent on the LOX-1 receptor and downstream RhoA signaling.
Topics: Animals; Arginase; Atherosclerosis; Cells, Cultured; Cholesterol, Dietary; Endothelial Cells; Enzyme Activation; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, LDL; Lovastatin; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Microtubules; Nitric Oxide; Protein Transport; rhoA GTP-Binding Protein; RNA Interference; Scavenger Receptors, Class E; Signal Transduction; Simvastatin; Superoxides; Transfection | 2011 |
Simvastatin reduces atherogenesis and promotes the expression of hepatic genes associated with reverse cholesterol transport in apoE-knockout mice fed high-fat diet.
Topics: Animals; Aorta; Apolipoprotein A-I; Apolipoproteins E; Atherosclerosis; ATP Binding Cassette Transporter 1; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 5; ATP-Binding Cassette Sub-Family B Member 4; ATP-Binding Cassette Transporters; Biological Transport; Cholesterol; Dietary Fats; Enzyme Assays; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Metabolism; Lipoproteins; Liver; Macrophages, Peritoneal; Male; Mice; Mice, Knockout; Phosphatidylcholine-Sterol O-Acyltransferase; Scavenger Receptors, Class B; Simvastatin; Up-Regulation | 2011 |
Validation of human ApoB and ApoAI immunoturbidity assays for non-human primate dyslipidemia and atherosclerosis research.
Topics: Animals; Apolipoprotein A-I; Apolipoproteins B; Atherosclerosis; Biomarkers; Calibration; Disease Models, Animal; Dyslipidemias; Electrophoresis, Polyacrylamide Gel; Enzyme-Linked Immunosorbent Assay; Haplorhini; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunoassay; Mass Spectrometry; Nephelometry and Turbidimetry; Predictive Value of Tests; Reproducibility of Results; Simvastatin | 2011 |
Statin/ezetimibe combination therapy: emerging evidence.
Topics: Anticholesteremic Agents; Atherosclerosis; Azetidines; Drug Combinations; Ezetimibe, Simvastatin Drug Combination; Humans; Simvastatin | 2011 |
Cholesterol-lowering strategies reduce vascular LRP1 overexpression induced by hypercholesterolaemia.
Topics: Animals; Atherosclerosis; Cholesterol; Endothelium, Vascular; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Low Density Lipoprotein Receptor-Related Protein-1; Male; Rabbits; Real-Time Polymerase Chain Reaction; Simvastatin | 2011 |
Synergistic effect of liver X receptor activation and simvastatin on plaque regression and stabilization: an magnetic resonance imaging study in a model of advanced atherosclerosis.
Topics: Animals; Anticholesteremic Agents; Aorta, Abdominal; Aortic Diseases; Atherosclerosis; Chemokine CCL2; Cyclooxygenase 2; Disease Progression; Drug Combinations; Drug Synergism; Indazoles; Liver X Receptors; Magnetic Resonance Angiography; Orphan Nuclear Receptors; Plaque, Atherosclerotic; Rabbits; Random Allocation; Simvastatin; Thromboplastin; Up-Regulation | 2012 |
Therapy and clinical trials: aggressive statin therapy versus combined and emerging approaches.
Topics: Animals; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Clinical Trials as Topic; Dyslipidemias; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2011 |
The SHARP trial: lessons learnt; answers and more questions!
Topics: Atherosclerosis; Azetidines; Clinical Trials as Topic; Drug Combinations; Ezetimibe, Simvastatin Drug Combination; Humans; Hypolipidemic Agents; Kidney Failure, Chronic; Learning; Simvastatin | 2012 |
Naringin ameliorates atherogenic dyslipidemia but not hyperglycemia in rats with type 1 diabetes.
Topics: Animals; Atherosclerosis; Blood Glucose; Cholesterol; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Dyslipidemias; Flavanones; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperglycemia; Hypoglycemic Agents; Insulin; Male; Rats; Rats, Wistar; Simvastatin; Streptozocin | 2012 |
Simvastatin suppresses apoptosis in vulnerable atherosclerotic plaques through regulating the expression of p(53), Bcl-2 and Bcl-xL.
Topics: Animals; Aorta; Apolipoproteins E; Apoptosis; Atherosclerosis; bcl-X Protein; Blood Glucose; Brachiocephalic Trunk; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Mice; Mice, Knockout; Plaque, Atherosclerotic; Proto-Oncogene Proteins c-bcl-2; Simvastatin; Tumor Suppressor Protein p53 | 2012 |
The pleiotropic effects of statins in the prevention of atherosclerosis : Editorial to: "Simvastatin suppresses apoptosis in vulnerable atherosclerotic plaques through regulating the expression of p53, Bcl-2 en Bcl-xL" by Weiwei Qin et al.
Topics: Animals; Apoptosis; Atherosclerosis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Plaque, Atherosclerotic; Simvastatin | 2012 |
Effect of Chinese drugs for activating blood circulation and detoxifying on indices of thrombosis, inflammatory reaction, and tissue damage in a rabbit model of toxin-heat and blood stasis syndrome.
Topics: Analysis of Variance; Animals; Atherosclerosis; Blood Circulation; Disease Models, Animal; Drugs, Chinese Herbal; Endothelium, Vascular; Immunohistochemistry; Inflammation; Male; Rabbits; Random Allocation; Sensitivity and Specificity; Simvastatin; Systemic Inflammatory Response Syndrome; Thrombosis | 2013 |
Prostaglandin E1 dose-dependently promotes stability of atherosclerotic plaque in a rabbit model.
Topics: Alprostadil; Angioplasty, Balloon; Animals; Anti-Inflammatory Agents; Aorta, Abdominal; Aortic Diseases; Atherosclerosis; Cardiovascular Agents; Chemokine CCL2; Cholesterol, Dietary; Cytokines; Daboia; Disease Models, Animal; Disease Progression; Dose-Response Relationship, Drug; Down-Regulation; Fibrosis; Histamine; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation Mediators; Lipid Metabolism; Macrophages; Male; Matrix Metalloproteinase 1; Matrix Metalloproteinase 9; Plaque, Atherosclerotic; Rabbits; RNA, Messenger; Simvastatin; Viper Venoms | 2012 |
Effectiveness of lipid-lowering therapy with statins for secondary prevention of atherosclerosis--guidelines vs. reality.
Topics: Atherosclerosis; Atorvastatin; Cholesterol, LDL; Decision Making; Diet, Fat-Restricted; Diet, Reducing; Dose-Response Relationship, Drug; Female; Health Surveys; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Male; Middle Aged; Patient Compliance; Poland; Practice Guidelines as Topic; Practice Patterns, Physicians'; Pyrroles; Rural Population; Secondary Prevention; Simvastatin; Urban Population | 2012 |
Effect of Si-Miao-Yong-An on the stability of atherosclerotic plaque in a diet-induced rabbit model.
Topics: Animals; Anti-Inflammatory Agents; Aorta, Abdominal; Atherosclerosis; Blood Coagulation; Cholesterol, Dietary; Cholesterol, LDL; Cytokines; Drugs, Chinese Herbal; Inflammation; Inflammation Mediators; Lipids; Macrophages; Magnoliopsida; Male; Myocytes, Smooth Muscle; Phytotherapy; Plaque, Atherosclerotic; Rabbits; Simvastatin; Triglycerides | 2012 |
[Effects of Chinese herbal medicine Guanxinkang on expression of PPARγ-LXRα-ABCA1 pathway in ApoE-knockout mice with atherosclerosis].
Topics: Animals; Apolipoproteins E; Atherosclerosis; ATP-Binding Cassette Transporters; Drugs, Chinese Herbal; Lipid Metabolism; Liver X Receptors; Mice; Mice, Inbred C57BL; Mice, Knockout; Orphan Nuclear Receptors; PPAR gamma; Random Allocation; Simvastatin | 2012 |
Simvastatin inhibits the pro-inflammatory and pro-thrombotic effects of IL-17 and TNF-α on endothelial cells.
Topics: Anti-Inflammatory Agents; Antibodies, Monoclonal; Anticholesteremic Agents; Antirheumatic Agents; Atherosclerosis; Drug Interactions; Endothelial Cells; Gene Expression; Human Umbilical Vein Endothelial Cells; Humans; Infliximab; Interleukin-17; Interleukin-6; Interleukin-8; Platelet Aggregation; Simvastatin; Thrombosis; Tumor Necrosis Factor-alpha | 2013 |
Inhibitory effect of the combination therapy of simvastatin and pinocembrin on atherosclerosis in ApoE-deficient mice.
Topics: Animals; Apolipoproteins E; Atherosclerosis; Diet, High-Fat; Drug Combinations; Endothelins; Flavanones; Humans; Lipids; Malondialdehyde; Mice; Nitric Oxide; Simvastatin; Superoxide Dismutase; Vascular Endothelial Growth Factor A | 2012 |
Use of secondary preventive medications in patients with atherosclerotic disease in urban China: a cross-sectional study of 16, 860 patients.
Topics: Aged; Aged, 80 and over; Atherosclerosis; Atorvastatin; Cerebrovascular Disorders; Coronary Artery Disease; Cross-Sectional Studies; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Peripheral Vascular Diseases; Pyrroles; Secondary Prevention; Simvastatin | 2012 |
Arterial retention of remnant lipoproteins ex vivo is increased in insulin resistance because of increased arterial biglycan and production of cholesterol-rich atherogenic particles that can be improved by ezetimibe in the JCR:LA-cp rat.
Topics: Animals; Anticholesteremic Agents; Arteries; Atherosclerosis; Azetidines; Biglycan; Cholesterol; Ezetimibe; Insulin Resistance; Lipoproteins; Male; Metabolic Syndrome; Rats; Simvastatin | 2012 |
Targeting healthcare disparities: an integrated model to improve treatment rates of dyslipidemia in African American patients.
Topics: Alcohol Drinking; Ambulatory Care; Atherosclerosis; Black People; Cholesterol, LDL; Clinical Protocols; Coronary Artery Disease; Curriculum; Diabetes Mellitus; Diet; Dyslipidemias; Female; Georgia; Humans; Hypolipidemic Agents; Internal Medicine; Internship and Residency; Male; Middle Aged; Patient Education as Topic; Risk Factors; Simvastatin; Smoking | 2005 |
Therapy and clinical trials.
Topics: Anticholesteremic Agents; Atherosclerosis; Azetidines; Clinical Trials as Topic; Ezetimibe; Humans; Hypercholesterolemia; Simvastatin | 2005 |
MDOC and atorvastatin have potential antiinflammatory effects in vascular endothelium of apoE-/- mouse model of atherosclerosis.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents; Apolipoproteins E; Atherosclerosis; Atorvastatin; Cellulose, Oxidized; Diet; Disease Models, Animal; Endothelium, Vascular; Heptanoic Acids; Hyperlipidemias; Intercellular Adhesion Molecule-1; Lipoproteins; Male; Mice; Mice, Knockout; Pyrroles; Simvastatin; Triglycerides; Vascular Cell Adhesion Molecule-1 | 2006 |
[Drug combinations: statins and niacin].
Topics: Age Distribution; Atherosclerosis; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Drug Interactions; Drug Therapy, Combination; Dyslipidemias; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Niacin; Pyrroles; Sex Factors; Simvastatin | 2005 |
Interferon-gamma induces major histocompatibility class II transactivator (CIITA), which mediates collagen repression and major histocompatibility class II activation by human aortic smooth muscle cells.
Topics: Aorta; Atherosclerosis; Cells, Cultured; Collagen; DNA-Binding Proteins; Gene Expression Regulation; Genes, MHC Class II; HLA-DR Antigens; Humans; Interferon-gamma; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Nuclear Proteins; Promoter Regions, Genetic; Regulatory Factor X Transcription Factors; RNA, Messenger; Simvastatin; Trans-Activators | 2006 |
Chromosomal damage and atherosclerosis. A protective effect from simvastatin.
Topics: Atherosclerosis; Carotid Arteries; Cells, Cultured; Chromosome Aberrations; Dose-Response Relationship, Drug; Female; Hemodiafiltration; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Failure, Chronic; Lymphocytes; Male; Middle Aged; Mitotic Index; Simvastatin; Sister Chromatid Exchange; Ultrasonography | 2006 |
Statin treatment is not associated with consistent alterations in inflammatory status of carotid atherosclerotic plaques: a retrospective study in 378 patients undergoing carotid endarterectomy.
Topics: Antigens, CD; Antigens, Differentiation, Myelomonocytic; Atherosclerosis; Atorvastatin; Carotid Arteries; Carotid Artery Diseases; Cytokines; Dose-Response Relationship, Drug; Endarterectomy, Carotid; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunohistochemistry; Inflammation; Macrophages; Peptide Hydrolases; Phenotype; Pravastatin; Pyrroles; Retrospective Studies; Simvastatin | 2006 |
Effects of simvastatin on NF-kappaB-DNA binding activity and monocyte chemoattractant protein-1 expression in a rabbit model of atherosclerosis.
Topics: Animals; Atherosclerosis; Chemokine CCL2; Cholesterol; DNA-Binding Proteins; Electrophoretic Mobility Shift Assay; Hypolipidemic Agents; Immunohistochemistry; Male; NF-kappa B; Protein Binding; Rabbits; Random Allocation; Simvastatin | 2006 |
An anthocyanin-rich extract from black rice enhances atherosclerotic plaque stabilization in apolipoprotein E-deficient mice.
Topics: Animals; Anthocyanins; Anticholesteremic Agents; Apolipoproteins E; Atherosclerosis; Diet; Male; Mice; Mice, Inbred C57BL; Muscle, Smooth, Vascular; Oryza; Phytotherapy; Plant Extracts; Simvastatin | 2006 |
Simvastatin treatment ameliorates autoimmune disease associated with accelerated atherosclerosis in a murine lupus model.
Topics: Animals; Apolipoproteins E; Atherosclerosis; Cell Proliferation; Cholesterol; Disease Models, Animal; Lupus Erythematosus, Systemic; Lymph Nodes; Mice; Mice, Inbred C57BL; Mice, Knockout; Phenotype; Simvastatin; Th2 Cells; Up-Regulation | 2006 |
Association of high-density lipoprotein levels and carotid atherosclerotic plaque characteristics by magnetic resonance imaging.
Topics: Adult; Atherosclerosis; Carotid Artery Diseases; Chi-Square Distribution; Coronary Angiography; Female; Humans; Hypolipidemic Agents; Lipoproteins, HDL; Magnetic Resonance Imaging; Male; Middle Aged; Niacin; Simvastatin | 2007 |
Tumor necrosis factor-alpha as a potential target in the treatment of systemic lupus erythematosus: a role for the HMG-CoA reductase inhibitor simvastatin.
Topics: Adult; Atherosclerosis; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lupus Erythematosus, Systemic; Middle Aged; Simvastatin; Tumor Necrosis Factor-alpha | 2006 |
Enhanced expression of the homeostatic chemokines CCL19 and CCL21 in clinical and experimental atherosclerosis: possible pathogenic role in plaque destabilization.
Topics: Angioplasty, Balloon, Coronary; Animals; Apolipoproteins E; Atherosclerosis; Atorvastatin; Biopsy, Needle; Cells, Cultured; Chemokine CCL19; Chemokine CCL21; Chemokines, CC; Coronary Disease; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Gene Expression Regulation; Heptanoic Acids; Humans; Immunohistochemistry; In Vitro Techniques; Leukocytes, Mononuclear; Mice; Mice, Transgenic; Prognosis; Pyrroles; Receptors, CCR7; Receptors, Chemokine; Reference Values; Risk Factors; RNA, Messenger; Sensitivity and Specificity; Simvastatin; Treatment Outcome | 2007 |
Strong suppression of high-sensitivity C-reactive protein level and its mediated pro-atherosclerotic effects with simvastatin: in vivo and in vitro studies.
Topics: Analysis of Variance; Atherosclerosis; Blotting, Western; C-Reactive Protein; Case-Control Studies; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; In Vitro Techniques; Intercellular Adhesion Molecule-1; Male; Middle Aged; Risk Factors; Simvastatin; Umbilical Veins; Vascular Cell Adhesion Molecule-1 | 2007 |
[Effects of Tongxinluo and Simvastatin on the stabilization of vulnerable atherosclerotic plaques of aorta in aortic atherosclerosis and molecular mechanism thereof: a comparative study with rabbits].
Topics: Animals; Aorta; Atherosclerosis; Blotting, Western; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cyclooxygenase 2; Disease Models, Animal; Drugs, Chinese Herbal; Fas Ligand Protein; Gene Expression; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Matrix Metalloproteinase 1; Phytotherapy; Proto-Oncogene Proteins c-bcl-2; Rabbits; Random Allocation; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Simvastatin; Triglycerides | 2006 |
Pharmacological inhibition of RhoA signaling prevents connective tissue growth factor induction in endothelial cells exposed to non-uniform shear stress.
Topics: Atherosclerosis; Cells, Cultured; Connective Tissue Growth Factor; Endothelial Cells; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immediate-Early Proteins; Intercellular Signaling Peptides and Proteins; Rheology; rho-Associated Kinases; rhoA GTP-Binding Protein; Signal Transduction; Simvastatin; Umbilical Veins | 2008 |
Simvastatin and plaque inflammation.
Topics: Atherosclerosis; Fluorodeoxyglucose F18; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Positron-Emission Tomography; Radiopharmaceuticals; Simvastatin | 2007 |
HMG-CoA reductase inhibitors reduce nicotine-induced expression of cellular adhesion molecules in cultured human coronary endothelial cells.
Topics: Atherosclerosis; Cell Adhesion; Cells, Cultured; Coronary Vessels; Dose-Response Relationship, Drug; Endothelial Cells; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Intercellular Adhesion Molecule-1; Leukocytes; Lovastatin; NF-kappa B; Nicotine; Nicotinic Agonists; Pravastatin; Protein Kinase C; Reactive Oxygen Species; rhoA GTP-Binding Protein; RNA, Messenger; Signal Transduction; Simvastatin; Smoking; Superoxide Dismutase; Time Factors; Vascular Cell Adhesion Molecule-1 | 2007 |
Cholestin (Monascus purpureus rice) inhibits homocysteine-induced reactive oxygen species generation, nuclear factor-kappaB activation, and vascular cell adhesion molecule-1 expression in human aortic endothelial cells.
Topics: Anti-Inflammatory Agents; Aorta; Atherosclerosis; Biological Products; Cell Adhesion; Chromogranin A; Endothelial Cells; Gene Expression Regulation; Homocysteine; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; NF-kappa B; Peptide Fragments; Reactive Oxygen Species; Risk Factors; RNA, Messenger; Simvastatin; U937 Cells; Vascular Cell Adhesion Molecule-1 | 2008 |
2,3,4',5-Tetrahydroxystilbene-2-O-beta-D-glucoside suppresses matrix metalloproteinase expression and inflammation in atherosclerotic rats.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Atherosclerosis; Dose-Response Relationship, Drug; Gene Expression Regulation, Enzymologic; Glucosides; Inflammation; Male; Matrix Metalloproteinases; Rats; Rats, Sprague-Dawley; Simvastatin; Stilbenes | 2008 |
3-(4'-hydroxyl-3',5'-dimethoxyphenyl)propionic acid, an active principle of kimchi, inhibits development of atherosclerosis in rabbits.
Topics: Animals; Antioxidants; Aorta; Atherosclerosis; Brassica; Diet; Hypercholesterolemia; Korea; Lipid Peroxidation; Lipids; Male; Phenyl Ethers; Propionates; Rabbits; Simvastatin | 2007 |
Decreased C-reactive protein-induced resistin production in human monocytes by simvastatin.
Topics: Animals; Atherosclerosis; C-Reactive Protein; Cells, Cultured; Coronary Disease; Diterpenes; Dose-Response Relationship, Drug; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin Resistance; Mevalonic Acid; Monocytes; Polyisoprenyl Phosphates; Resistin; Risk Factors; Rodentia; Signal Transduction; Simvastatin; Time Factors; Up-Regulation | 2007 |
Macrophage infiltration, lectin-like oxidized-LDL receptor-1, and monocyte chemoattractant protein-1 are reduced by chronic HMG-CoA reductase inhibition.
Topics: Animals; Atherosclerosis; Carotid Artery, Common; Chemokine CCL2; Cholesterol; Cholesterol, Dietary; Depression, Chemical; Diet; Dietary Fats; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunohistochemistry; Leukocyte Count; Lipids; Macrophages; Male; Rats; Rats, Inbred SHR; Simvastatin; Triglycerides | 2007 |
The in vitro and ex vivo antioxidant properties, hypolipidaemic and antiatherosclerotic activities of water extract of Moringa oleifera Lam. leaves.
Topics: Animals; Antioxidants; Atherosclerosis; Biphenyl Compounds; Body Weight; Cholesterol; Cholesterol, Dietary; Humans; Hypolipidemic Agents; Lipids; Lipoproteins, LDL; Male; Moringa oleifera; Picrates; Plant Extracts; Plant Leaves; Rabbits; Simvastatin; Thiobarbituric Acid Reactive Substances; Vitamin E; Water | 2008 |
Effect of simvastatin in apolipoprotein E deficient mice with surgically induced chronic renal failure.
Topics: Animals; Apolipoproteins E; Atherosclerosis; Calcinosis; Disease Models, Animal; Female; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Failure, Chronic; Male; Mice; Oxidative Stress; Simvastatin | 2008 |
Critical lessons from the ENHANCE trial.
Topics: Anticholesteremic Agents; Atherosclerosis; Azetidines; Carotid Arteries; Conflict of Interest; Data Interpretation, Statistical; Drug Approval; Drug Industry; Ezetimibe; Humans; Hyperlipoproteinemia Type II; Mass Media; Randomized Controlled Trials as Topic; Simvastatin; Ultrasonography | 2008 |
LDL induces parathyroid hormone-related protein expression in vascular smooth muscle cells: Modulation by simvastatin.
Topics: Animals; Atherosclerosis; Cells, Cultured; Disease Models, Animal; Femoral Artery; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, LDL; Macrophages; Male; Mevalonic Acid; Muscle Cells; Muscle, Smooth, Vascular; Parathyroid Hormone-Related Protein; Polyisoprenyl Phosphates; Rabbits; Receptor, Parathyroid Hormone, Type 1; RNA, Small Interfering; Simvastatin; Tunica Intima; Up-Regulation | 2008 |
Aqueous extract of rhubarb stabilizes vulnerable atherosclerotic plaques due to depression of inflammation and lipid accumulation.
Topics: Animals; Anticholesteremic Agents; Aorta, Abdominal; Aortic Rupture; Atherosclerosis; Cholesterol, HDL; Cholesterol, LDL; Constriction, Pathologic; Disease Models, Animal; Gene Expression; Histamine; Medicine, Chinese Traditional; NF-kappa B; Phytotherapy; Plant Extracts; Rabbits; Rheum; RNA, Messenger; Simvastatin; Toll-Like Receptors; Viper Venoms | 2008 |
After ENHANCE: is more LDL cholesterol lowering even better?
Topics: Anticholesteremic Agents; Atherosclerosis; Azetidines; Biomarkers; Carotid Artery Diseases; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Inflammation; Lipid Metabolism; Simvastatin | 2008 |
Diabetes reduces aortic endothelial gap junctions in ApoE-deficient mice: simvastatin exacerbates the reduction.
Topics: Animals; Aorta, Thoracic; Apolipoproteins E; Atherosclerosis; Blotting, Western; Connexins; Diabetes Mellitus, Experimental; Endothelium, Vascular; Gap Junction alpha-4 Protein; Gap Junction alpha-5 Protein; Gap Junctions; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Mice; Mice, Inbred C57BL; Microscopy, Confocal; Simvastatin | 2008 |